Document:

<PAGE>

                                                                   Exhibit 10.20

                          SPONSORED RESEARCH AGREEMENT

         RESEARCH AGREEMENT, effective on the date of last signature below, by
and between The University of North Carolina at Chapel Hill, having an address
at 308 Bynum Hall, Chapel Hill, North Carolina (the "University"), and Boston
Biomedica, Inc., a corporation existing under the laws of the State of
Massachusetts, and having its principal place of business at 375 West Street,
West Bridgewater, MA 02379 (the "Sponsor"),

                                   WITNESSETH:

         WHEREAS, in pursuit of its educational purposes, which include research
and training, the University undertakes scholarly research and experimental
activities in a variety of academic disciplines; and
         WHEREAS, the Sponsor has funded, wishes to continue to fund, and
desires that the University undertake, a research program in accordance with
said research and training mission, which research program is described more
fully in Exhibit A, attached hereto and made a part hereof (hereinafter, the
"Research"); and
         WHEREAS, in furtherance of its scholarly research and instructional
interests, the University is willing to undertake the Research upon the terms
and conditions set forth below;
         NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, the parties hereto agree as follows:

1.       Scope of Research

         During the term of this Agreement, the University shall use its best
         efforts to perform the Research, as described in Exhibit A, attached
         hereto and made a part hereof. Notwithstanding the foregoing, the
         University makes no warranties or representations regarding its ability
         to achieve, nor shall it be bound hereby to accomplish, any particular
         research objective or results.

2.       Personnel

         The Research shall be performed by, and under the supervision and
         direction of, Dr. Kuo-Hsiung Lee, who shall be designated the Principal
         Investigator, together with such additional personnel as may be
         assigned by the University. Sponsor shall be notified as to the
         identity of the additional personnel and any personnel changes during
         the course of the contract. If for any reason the Principal
         Investigator is unable to continue to serve as the Principal
         Investigator, and a successor acceptable to both the University and the
         Sponsor is not available, this agreement may be terminated as provided
         in Article 10.2.
<PAGE>
                                                                               2

3.       University policies and Procedures

         All Research conducted hereunder shall be performed in accordance with
         established University policies and procedures, including, but not
         limited to, policies and procedures applicable to research involving
         human subjects, laboratory animals, and hazardous agents and materials.

4.       Budget and Payment Schedules

4.1      The Sponsor agrees to pay University, direct and indirect costs, in
         connection with the Research in accordance with the Budget attached
         hereto as Exhibit B. This budget covers all work described in Exhibit
         A, including the discovery and development of novel compounds against
         HIV and one additional virus or disease selected by Sponsor. In
         addition to the Research described in Exhibit A, these funds will allow
         the Principal Investigator to generate approximately 10 grams of each
         of four separate compounds, per year. If Sponsor wishes to generate
         additional quantities or additional compounds, other resources must be
         committed towards this effort. Sponsor, at its sole discretion, may
         choose to expand the research scope as follows:

<TABLE>
<CAPTION>
         -----------------------------------------------------------------------
         TYPE OF EXTENSION                           Additional Direct Costs
         OF RESEARCH SCOPE                           -----------------------
                                                             Per Year
                                                             --------
<S>                                                  <C>
         additional disease state (max. of two)      $50,000

         additional bulk synthesis of compounds      $5,000-$7,500 (approximate)
         -----------------------------------------------------------------------
</TABLE>

4.2      For the purposes of this Agreement, "disease state" shall mean an
         individual virus or disease (e.g. HIV, HCV, breast cancer, lymphoma,
         etc.) for which compounds are being designed, under the Research, to
         serve as therapeutic agents.

4.3      The University and Sponsor have agreed that the indirect cost rates for
         the Research shall be added to the direct costs listed above and shall
         be charged incrementally per year according to the following schedule

         Year1:            10% Total Direct Costs
         Year 2:           17.5% Total Direct Costs
         Year 3:           25% Total Direct Costs
         Option Year 1:    35% Total Direct Costs
         Option Year 2:    Full UNC Negotiated Rate

<PAGE>
                                                                               3

         Any modifications to the above shall be made only upon completion of a
         written amendment to this Agreement executed by the University, the
         Sponsor, and the Principal Investigator.

4.4      The University may submit to the Sponsor at any time, and the Sponsor
         may at its discretion approve in writing, requests for additional
         funds. However, the Sponsor is not liable for any cost in excess of the
         amount specified herein, unless this Agreement is modified to indicate
         such in writing by both parties. All checks shall be made payable to
         The University of North Carolina at Chapel Hill, shall include
         reference to the University, Principal Investigator and his department,
         and shall be sent to: S. Kent Walker, 440 W. Franklin St., CB#1350,
         UNC-CH, Chapel Hill, NC 27599-1350. Payments shall be made in
         accordance with the following schedule: one-quarter (1/4) of the annual
         budget on the date of signing of the agreement, and equal quarterly
         payments thereafter for each funding year of the agreement.

5.       Research Reports

         The Principal Investigator shall furnish to the Sponsor during the term
         of his Agreement informal written reports at least twice per year
         regarding the progress of the Research. A final report setting forth
         the significant research findings shall be prepared by the Principal
         Investigator and submitted to the Sponsor within ninety (90) days
         following the expiration of the term of this Agreement or the effective
         date of early termination, as set forth in Article 10.

6.       Publication

         The University reserves, on behalf of the Principal Investigator and
         other University employees and / or students, the right to disseminate
         information, or to publish any material resulting from the Research
         without need for approval by the Sponsor. However, the University shall
         provide the Sponsor with a copy of any proposed publication forty-five
         (45) days in advance of the proposed publication date. The Sponsor may
         request, and the University shall agree to, a delay of such proposed
         publication for an additional period, not to exceed forty-five (45)
         days, in order to protect the potential patentability of any invention
         described therein. The Sponsor, at its election, shall be entitled to
         receive in any such publication an acknowledgment of its sponsorship of
         the Research. It is specifically agreed that nothing contained in this
         agreement will interfere with the publication or oral defense of
         research theses and dissertations of graduate students.

<PAGE>
                                                                               4

7.       Proprietary Information

7.1      University shall disclose any new invention under this Agreement to
         Licensee:
         (a) within two months after the inventor discloses it to the
             University's Office of Technology Development.
         (b) at least two months prior to any intended public disclosure of all
             or part of the invention; and
         (c) at least two weeks prior to submission for publication of any
             manuscript or abstract which discloses all or part of the invention

7.2      The disclosure under Article 7.1 shall be in writing and shall be
         sufficiently complete in technical detail to convey a clear
         understanding, to the extent known at the time of the disclosure, of
         all attributes associated with the invention, such that a patent
         application with meaningful claims can be drafted. It should also
         indicate the earliest expected date of public disclosure of the
         invention.

7.3      The University will promptly inform Company of the submission of any
         abstract or manuscript for publication and its acceptance thereof.

7.4      The invention will not be publicly disclosed for 60 days after Company
         has received a description of the invention. Company shall remove any
         of its Confidential Information from the proposed public disclosure or
         file a patent application sufficiently covering the invention within
         this two month review period. If Company wishes to further delay
         publication in order to draft a thorough patent application describing
         the invention it must request such a delay to University in writing,
         and University's approval shall not be unreasonably withheld. In no way
         shall the total delay be more than ninety (90) days from the initial
         disclosure of invention to company except with the written mutual
         consent of both parties.

7.5      All confidential information of either party disclosed to the other
         party in connection with the Research hereunder will be treated by the
         receiving party as confidential and restricted in its use to only those
         uses contemplated by the terms of this Agreement. Any information which
         is to be treated as confidential must be clearly marked as confidential
         prior to transmittal to the other party. If such confidential
         information is disclosed orally, it shall be identified as being
         confidential at the time of disclosure, and shall thereafter be reduced
         to writing within 30 days, marked as confidential, and transmitted to
         the receiving party. The Sponsor may submit confidential information
         only to the Principal Investigator, who shall be free to refuse to
         accept such confidential information. The obligations of this paragraph
         shall survive and continue for three (3) years after termination of
         this Agreement. Specifically excluded from such confidential treatment
         shall be information which:
         (a) as of the date of disclosure and / or delivery, is already known to
             the party receiving such information;
<PAGE>
                                                                               5

         (b) is or becomes part of the public domain, through no fault of the
             receiving party;
         (c) is lawfully disclosed to the receiving party by a third party who
             is not obligated to retain such information in confidence;
         (d) is independently developed at the receiving party by someone not
             privy to the confidential information, or
         (e) either party is required by law to provide.

8.       Results of the Research

8.1      "New Invention or Discovery" shall mean any invention or discovery
         conceived or reduced to practice during and as a part of the Research
         performed pursuant to this Agreement by Institution's Principal
         Investigator, faculty, staff, employees, or students or jointly by such
         an individual or individuals with one or more employees of the Sponsor.
         New Inventions or Discoveries made solely by Institution's Principal
         Investigator, faculty, staff, employees, or students shall be the sole
         property of the Institution. New Inventions or Discoveries made jointly
         by Institution's Principal Investigator, faculty, staff, employees, or
         students with one or more employees of the Sponsor shall be owned
         jointly by the Institution and the Sponsor. New Inventions or
         Discoveries made solely by employees of Sponsor shall be the sole
         property of Sponsor.

8.2      The University shall promptly disclose to the Sponsor in writing any
         New Invention or Discovery which is subject to this Agreement. To the
         extent that it has the legal right to do so, the University shall, upon
         request of the Sponsor, grant the Sponsor the first Option for an
         exclusive license to the University's right, title, and interest in any
         such New Invention or Discovery under an Exclusive License Agreement to
         be negotiated in accordance with the attached License Agreement and
         under terms no less favorable to the Sponsor than those in the attached
         License Agreement. Sponsor shall have six months to determine whether
         to exercise this Option. If Sponsor declines to exercise its option to
         any New Invention or Discovery University shall, at its own discretion,
         be free to license the University's right, title, and interest in such
         New Invention or Discovery to a third party, exclusively or
         non-exclusively.

9.       Ownership of Property

         Title to any equipment purchased or manufactured in the performance of
         the work funded under this agreement shall vest in the University.

<PAGE>
                                                                               6

10.      Term and Termination

10.1     This Agreement shall be effective for three (3) years from the date of
         last signature below, with two additional one-year option periods that
         may be exercised by Sponsor by providing written notice to University
         within sixty (60) days of the termination date above. Notwithstanding
         the foregoing, this Agreement may be extended thereafter by mutual
         agreement of the parties in writing.

10.2     Notwithstanding the foregoing, this Agreement may be terminated by
         either party at any time upon sixty (60) days advance written notice to
         the other party, however, the provisions of paragraphs 7, 8, 9, 12, 14,
         15, and 20 shall survive such termination. Upon receipt of notice of
         early termination from Sponsor, the University shall use its best
         efforts promptly to limit or terminate any outstanding commitments and
         to conclude the work. All costs associated with such termination shall
         be reimbursable, including, without limitation, all non-reimbursed
         costs and non-cancelable commitments incurred prior to the receipt of
         the notice of termination, such reimbursement together with other
         payments not to exceed the total estimated project cost specified in
         Article 4.

11.      Notices

         Any notices given under this Agreement shall be in writing and shall be
         deemed delivered when sent by first-class mail, postage paid, addressed
         to the parties as follows (or at such other addresses as the parties
         may notify each other of in writing):

         The University of North Carolina at Chapel Hill:

         Dr. Robert P. Lowman
         Associate Vice Provost for Research
         Office of Research Services
         The University of North Carolina at Chapel Hill
         CB#4100, 300 Bynum Hall
         Chapel Hill, NC  27599-4100

         Sponsor:

         Richard T. Schumacher
         President and CEO
         Boston Biomedica, Inc.
         375 West Street
         West Bridgewater, MA  02379
<PAGE>
                                                                               7

12.      Use of University Name

         Sponsor shall not employ or use the name of the University in any
         promotional materials, advertising, or in any other manner without the
         prior express written permission of the University, except that Sponsor
         may, during the term of this Agreement, state that it is sponsoring the
         Research at the University. In no event shall the sponsoring of the
         Research be considered to be an endorsement by the University of any
         commercial product which may result, indirectly or directly, from the
         Research.

13.      Relationship of the Parties

         The University, for all purposes related to this Agreement, shall be
         deemed an independent contractor of the Sponsor, and nothing in this
         Agreement shall be deemed to create a relationship of employment or
         agency or to constitute the parties as partners or joint ventures.

14.      Indemnification

14.1     The Sponsor agrees to defend, indemnify and hold harmless the
         University, its employees, students and agents from and against any and
         all liablility claims, lawsuits, losses, demands, damages, costs and
         expenses, arising directly or indirectly out of the Research as
         described in Exhibit A, or the design, manufacture, sale or use of any
         embodiment or manifestation of said Research regardless of whether any
         and all such liability, claims, lawsuits, losses, demands, damages,
         costs and expenses arise in whole or in part from the negligence of any
         of the indemnified parties. Notwithstanding the foregoing, the Sponsor
         will not be responsible for any liablility, claims, lawsuits, losses,
         demands, damages, costs, and expenses which arise solely from (a) the
         gross negligence or intentional misconduct of University or the
         Principal Investigator; and (b) actions by University or the Principal
         Investigator in violation of applicable laws or regulations.
         Notwithstanding any provisions herein to the contrary, and subject to
         the provisions of the N.C. Tort Claims Act, G.S. 143-291 et seq., the
         University shall indemnify the Sponsor for any claims for injuries to
         persons or property damage which occur on the University premises or
         premises under the exclusive control of the University.

14.2     The Sponsor agrees to provide a diligent defense against any and all
         liability, claims, lawsuits, losses, demands, damages, costs, and
         expenses, brought against the indemnified parties with respect to the
         subject of the indemnity contained in Section 14.1, whether such claims
         of actions are rightfully or wrongfully brought or filed.
<PAGE>
                                                                               8

14.3     The University, on behalf of its employees, students and agents wishing
         collectively to be indemnified as provided in Sections 14.1 and 14.2
         shall:

         (a) promptly after receipt of notice of any all liability claims,
             lawsuits, losses, demands, damages, costs and expenses, or after
             the commencement of any action, suit or proceeding giving rise to
             the right of idemnification, notify the Sponsor, in writing, of
             said liability, claims, lawsuits, losses, demands, damages, costs,
             and expense and send to the Sponsor a copy of all papers served on
             the indemnified party; the University's failure to notify the
             Sponsor will not relieve the Sponsor from any liability to the
             indemnified party; and

         (b) permit the Sponsor to retain counsel of its choosing to represent
             the indemnified party (but in the event that the Sponsor does not
             select counsel to represent the indemnified party within ten (10)
             days, the indemnified party may select its own counsel, the fees
             and all costs of which counsel will be borne by the Sponsor); and

         (c) subject to the statutory authority of the Attorney General of the
             State of North Carolina, allow the Sponsor to retain exclusive
             control of any such liability, claims, lawsuits, losses, demands,
             damages, costs, and expenses, including the right to make any
             settlement, except that the Sponsor will not have the right to make
             any settlement or take any other action which would be deemed to
             confess wrongdoing by any of the indemnified parties or could
             reasonably be expected to have a negative effect on the reputation
             of one of the indemnified parties, without the prior written
             consent of University and the indemnified party involved.

15.      No Warranties

         The University makes no warranties, either express or implied, as to
         any matter, including, without limitation, the results of the research
         or any inventions or product, tangible or intangible, conceived,
         discovered or developed under this Agreement; or the merchantability or
         fitness for a particular purpose of the research results of any such
         invention or product. The University shall not be liable for any
         direct, consequential or other damages suffered by the Sponsor or by
         any Licensee or any others resulting from the use of the research
         results or any such invention or product.
<PAGE>
                                                                               9

16.      Force Major

         The University shall not be liable for any failure to perform as
         required by this Agreement, to the extent such failure to perform is
         caused by any reason beyond the University's control, or by reason of
         any of the following: labor disturbances or disputes of any kind,
         accidents, failure of any required governmental approval, civil
         disorders, acts of aggression, acts of God, energy or other
         conservation measures, failure of utilities, mechanical breakdowns,
         material shortage, disease, or similar occurrences.

17.      Severability

         In the event that a court of competent jurisdiction holds any provision
         of this Agreement to be invalid, such holding shall have no effect on
         the remaining provisions of this Agreement, and they shall continue in
         full force and effect.

18       Entire Agreement; Amendments

         This Agreement and the Exhibits hereto contain the entire agreement
         between the parties. No amendments or modifications to this Agreement
         shall be effective unless made in writing and signed by authorized
         representatives of both parties.

19       Similar Research

         Nothing in this Agreement shall be construed to limit the freedom of
         the University of one of its researchers who are participants under
         this Agreement, from engaging in similar research made under other
         grants, contracts or agreements with parties other than the Sponsor.

20.      Transfer of Sponsorship

         During the course of this agreement, the Sponsor may transfer its
         rights and obligations as Sponsor to a company formed by the Sponsor
         and in which the Sponsor has at least 40% ownership at the time of
         transfer, or another percent ownership interest agreed upon in writing
         by the Parties. Sponsor will notify the University and Principal
         Investigator in writing prior to any such transfer.

21.      Governing Law

         This Agreement shall be governed by and construed in accordance with
         the law of North Carolina.
<PAGE>
                                                                              10

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their duly authorized officers or representatives.

         THE UNIVERSITY OF NORTH CAROLINA        SPONSOR
         AT CHAPEL HILL

         By: _____________________               By:_____________________

         Robert P. Lowman, Ph.D.                 Richard T. Schumacher
         Associate Vice Provost                  President and CEO
         Office of Research Services

         Date: _____________________             Date: ___________________

         Consented to by Principal Investigator:

         Signature: __________________________________________
                       Dr. Kuo-Hsiung Lee
                       Kenan Professor of Medicinal Chemistry

         Date:        ________________________________________
<PAGE>
                                                                              11

                                    Exhibit A
                                    ---------

The objectives of this Research shall be to (1) discover and develop novel
compounds that have improved anti-HIV activity and activity against one
additional virus or disease selected by Sponsor within the first two years of
the Agreement; (2) design and synthesize analogs of compounds already discovered
as a result of previous research paid for by Sponsor [e.g. compounds disclosed
in the US Patent Nos. 5,612,341; 5,637,589; 5,679,828; 5,726,204, and 5,847,165;
and in the US Patent Application entitled "Acylated Betulin and Dihydrobetulin
Derivatives, Preparation Thereof and Use Thereof", Inventors: K-H Lee, I-C Sun,
H-K Wang, and L.M. Cosentino]; and (3) synthesize gram-scale quantities of four
compounds per year to undergo extensive testing. During the course of this
research, the University will transfer to the Sponsor compounds synthesized
under this Research Plan for testing by Sponsor. Sponsor may, at his own cost,
have these compounds tested by contract testing organizations or collaborators.
These tests may include screening the compounds against a variety of viruses in
order to select the additional anti-viral target referred to above.

Sponsor may choose to direct research towards additional viruses and / or
disease states (maximum of two) at any point during the Research. However, such
research must be agreed upon by Sponsor and University prior to initiation of a
new research plan, and the minimum cost for such research will be in accordance
with Article 4 above. Sponsor may, at its own discretion, request additional
compounds as discussed in research objective #3 (in this Exhibit A) above,
provided that Sponsor pays all costs of the synthesis above and beyond the
agreed-upon costs herein.
<PAGE>
                                                                              12

                                    EXHIBIT B

<TABLE>
<CAPTION>
                                                        Year 1       Year 2       Year 3      Combined
<S>                                                    <C>          <C>          <C>         <C>
Salary + fringes for 2 post-docs @ 30,000               60,000       60,000       60,000      180,000
Salary + fringes for 2 graduate students @ 14,834       29,668       29,668       29,668       89,004
Tuition for two graduate students                       18,332       18,332       18,332       54,996

Supplies, starting materials for four target
compounds / year, miscellaneous expenses                42,000       42,000       42,000      126,000

TOTAL DIRECT COSTS                                     150,000      150,000      150,000      450,000

Indirect Costs (10% Yr 1, 17.5% Yr 2, 25% Yr 3          15,000       26,250       37,500       78,750

TOTAL COSTS                                            165,000      176,250      187,500      528,750
</TABLE><PAGE>

                                                      CONTRACT NO. N01-AI-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

                       DETAILED TABLE OF CONTRACT CONTENTS

<TABLE>
<S>                                                                                      <C>
PART I - THE SCHEDULE

      SECTION A - SOLICITATION/CONTRACT FORM

      SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS..................................  4
            ARTICLE B.1.  BRIEF DESCRIPTION OF SUPPLIES OR SERVICES......................  4
            ARTICLE B.2.  ESTIMATED COST AND FIXED FEE...................................  4
            ARTICLE B.3.  PROVISIONS APPLICABLE TO DIRECT COSTS..........................  4
            ARTICLE B.4.  ADVANCE UNDERSTANDINGS.........................................  6

      SECTION C - STATEMENT OF WORK......................................................  7
            ARTICLE C.1.  STATEMENT OF WORK..............................................  7
            ARTICLE C.2.  REPORTING REQUIREMENTS.........................................  7

      SECTION D - PACKAGING, MARKING AND SHIPPING........................................  9

      SECTION E - INSPECTION AND ACCEPTANCE..............................................  9

      SECTION F - DELIVERIES OR PERFORMANCE.............................................. 10
            ARTICLE F.1.  DELIVERIES..................................................... 10
            ARTICLE F.2.  CLAUSES INCORPORATED BY REFERENCE.............................. 10

      SECTION G - CONTRACT ADMINISTRATION DATA........................................... 11
            ARTICLE G.1.  PROJECT OFFICER................................................ 11
            ARTICLE G.2.  KEY PERSONNEL.................................................. 11
            ARTICLE G.3.  INVOICE SUBMISSION/CONTRACT FINANCING REQUEST AND CONTRACT
                              FINANCIAL REPORT........................................... 12
            ARTICLE G.4.  INDIRECT COST RATES............................................ 13
            ARTICLE G.5.  GOVERNMENT PROPERTY............................................ 13
            ARTICLE G.6.  POST AWARD EVALUATION OF PAST PERFORMANCE...................... 14

      SECTION H - SPECIAL CONTRACT REQUIREMENTS.......................................... 15
            ARTICLE H.1.  REIMBURSEMENT OF COSTS FOR INDEPENDENT RESEARCH AND
                              DEVELOPMENT PROJECTS....................................... 15
            ARTICLE H.2.  HUMAN SUBJECTS................................................. 15
            ARTICLE H.3.  CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH.............. 15
            ARTICLE H.4.  NEEDLE EXCHANGE................................................ 16
            ARTICLE H.5.  SALARY RATE LIMITATION LEGISLATION PROVISIONS.................. 16
            ARTICLE H.6.  EPA ENERGY STAR REQUIREMENTS................................... 16
            ARTICLE H.7.  PUBLICATION AND PUBLICITY...................................... 16
            ARTICLE H.8.  PRESS RELEASES................................................. 17
            ARTICLE H.9.  REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE............. 17
            ARTICLE H.10. YEAR 2000 COMPLIANCE........................................... 17

PART II - CONTRACT CLAUSES............................................................... 19

      SECTION I - CONTRACT CLAUSES....................................................... 19
            ARTICLE I.1.  GENERAL CLAUSES FOR A COST-REIMBURSEMENT SERVICE CONTRACT ..... 19
            ARTICLE I.2  AUTHORIZED SUBSTITUTION OF CLAUSES.............................. 22
            ARTICLE I.3.  ADDITIONAL CONTRACT CLAUSES.................................... 22
</TABLE>

                                       1
<PAGE>

<TABLE>
<S>                                                                                      <C>
            ARTICLE I.4.  ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT.......... 23

PART III................................................................................. 25

      SECTION J - LIST OF ATTACHMENTS.................................................... 25

PART IV.................................................................................. 25

      SECTION K - REPRESENTATIONS AND CERTIFICATIONS..................................... 25

</TABLE>

                                       2
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS

ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

The purpose of this contract is to provide a specimen repository for domestic
and international HIV epidemiology studies, HIV vaccine trials, and other
clinical and prevention research studies supported by the DAIDS in the NIAID.

ARTICLE B.2. ESTIMATED COST AND FIXED FEE

a.    The estimated cost of this contract is $9,154,511.

b.    The fixed fee for this contract is $452,450. The fixed fee shall be paid
      in installments based on the percentage of completion of work, as
      determined by the Contracting Officer, and subject to the withholding
      provisions of the clauses ALLOWABLE COST AND PAYMENT and FIXED FEE
      referenced in the General Clause Listing in Part II, ARTICLE I.1. of this
      contract. Payment of fixed fee shall not be made in less than monthly
      increments.

c.    The Government's obligation, represented by the sum of the estimated cost
      plus fixed fee, is $9,606,961.

d.    Total funds currently available for payment and allotted to this contract
      are $1,295,817, of which $1,241,460 represents the estimated costs, and
      of which $54,357 represents the fixed fee. For further provisions on
      funding, see the LIMITATION OF FUNDS clause referenced in Part II, ARTICLE
      I.2. Authorized Substitutions of Clauses.

e.    It is estimated that the amount currently allotted will cover performance
      of the contract through August 15, 2000.

f.    Increments to be allotted to this contract are estimated as follows:

<TABLE>
<CAPTION>
                                                                                  Total Estimated
      FY          Period                 Estimated Cost          Fixed Fee        Cost Plus Fee
      --          ------                 --------------          ---------        ----------------
<S>               <C>                    <C>                     <C>              <C>
      1999        8/16/99-8/15/00        $1,241,460              $ 54,357         $1,295,817
      2000        8/16/00-8/15/01        $1,027,597              $ 52,767         $1,080,364
      2001        8/16/01-8/15/02        $1,242,260              $ 60,496         $1,302,756
      2002        8/16/02-8/15/03        $1,280,768              $ 64,427         $1,345,195
      2003        8/16/03-8/15/04        $1,340,291              $ 67,626         $1,407,917
      2004        8/16/04-8/15/05        $1,399,171              $ 70,776         $1,469,947
      2005        8/16/05-8/15/06        $1,622,964              $ 82,001         $1,704,965
                                         ----------              --------         ----------
                        TOTAL            $9,154,511              $452,450         $9,606,961

</TABLE>

g. The Contracting Officer may allot additional funds to the contract without
   the concurrence of the Contractor.

ARTICLE B.3. PROVISIONS APPLICABLE TO DIRECT COSTS

a.    ITEMS UNALLOWABLE UNLESS OTHERWISE PROVIDED

      Notwithstanding the clauses, ALLOWABLE COST AND PAYMENT and FIXED FEE,
      incorporated in this contract, unless authorized in writing by the
      Contracting Officer, the costs of the following items or activities shall
      be unallowable as direct costs:

                                       3
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

      (1)   Acquisition, by purchase or lease, of any interest in real property;

      (2)   Special rearrangement or alteration of facilities;

      (3)   Purchase or lease of ANY item of general purpose office furniture or
            office equipment regardless of dollar value. (General purpose
            equipment is defined as any items of personal property which are
            usable for purposes other than research, such as office equipment
            and furnishings, pocket calculators, etc.);

      (4)   Travel to attend general scientific meetings;

      (5)   Foreign travel - See b(2) below ;

      (6)   Patient care costs;

      (7)   Accountable Government property (defined as both real and personal
            property with an acquisition cost of $1,000 or more and a life
            expectancy of more than two years) and "sensitive items" (defined
            and listed in the Contractor's Guide for Control of Government
            Property), 1990, regardless of acquisition value;

      (8)   Consultants; and

      (9)   Subcontract(s).

b.    TRAVEL COSTS

      (1)   Domestic Travel

            (a)   Total expenditures for domestic travel (transportation,
                  lodging, subsistence, and incidental expenses) incurred in
                  direct performance of this contract shall not exceed $22,470
                  without the prior written approval of the Contracting Officer.

            (b)   The Contractor shall invoice and be reimbursed for all travel
                  costs in accordance with Federal Acquisition Regulation (FAR)
                  31.205-46.

      (2)   Foreign Travel

            Requests for foreign travel must be submitted at least six weeks
            in advance and shall contain the following: (a) meeting(s) and
            place(s) to be visited, with costs and dates; (b) name(s) and
            title(s) of Contractor personnel to travel and their functions in
            the contract project; (C) contract purposes to be served by the
            travel; (d) how travel of contractor personnel will benefit and
            contribute to accomplishing the contract project, or will otherwise
            justify the expenditure of NIH contract funds; (e) how such
            advantages justify the costs for travel and absence from the
            project of more than one person if such are suggested; and (f)
            what additional functions may be performed by the travelers to
            accomplish other purposes of the contract and thus further benefit
            the project.

      (3)   Government Discount Air Travel Rates

            (a)   To the maximum extent practicable consistent with travel
                  requirements, the Contractor agrees to use the reduced air
                  transportation rates and services provided through available
                  Government discount air fares. These fares are available only
                  for bona-fide employees' travel that is otherwise reimbursable
                  as a direct cost pursuant to this contract. The objective is
                  to achieve the lowest overall cost to the Contractor and,
                  thus, to the Government. The Contractor shall submit written
                  requests to the Contracting Officer for authorization to use
                  these rates. The request shall provide the full name of the
                  traveler(s), the number of the contract for which the travel
                  is being performed, the contract objective that is to be
                  fulfilled, and the dates during which the travel is to occur.
                  Contracting Officer approval, if given, will be on official
                  agency letterhead so that

                                       4
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

                  the letter can be presented to the airline as confirmation
                  of the authorization.

            (b)   Nothing in this clause shall authorize transportation or
                  services which are not otherwise reimbursable under this
                  contract. Nothing in this clause requires air carriers to make
                  available to the Contractor any government discount airfares.

ARTICLE B.4.  ADVANCE UNDERSTANDINGS

Other provisions of this contract notwithstanding, approval of the following
items within the limits set forth is hereby granted without further
authorization from the Contracting Officer.

a.    PRE-CONTRACT COSTS

      Within the dollar limitation set forth under SECTION B, ARTICLE B.2., the
      Contractor shall be entitled to reimbursement for costs incurred during
      the period August 16, 1999 through August 31, 1999, in an amount not to
      exceed $50,000, which if incurred after this contract had been entered
      into would have been reimbursable under the provisions of this contract.

b.    INDIRECT COSTS

      Pending the establishment of final indirect cost rates for any period,
      billing and reimbursement shall be made on the basis of provisional
      billing rates set forth in the Negotiated Indirect Cost Rate Agreement of
      April 1, 1998.

c.    SUBCONTRACT

      To negotiate a cost type subcontract with Information Management Services,
      Inc. (IMS) for Computerized biological specimen inventory and tracking for
      an amount not to exceed $275,628. Award of the subcontract shall not
      proceed without the prior written approval of the Contracting Officer upon
      review of the supporting documentation as required by the Subcontracts
      clause of the General Clauses incorporated in this contract. (After
      written approval of the subcontract by the Contracting Officer, a copy of
      the signed, approved subcontract shall be provided to the Contracting
      Officer.)

d.    USE OF SAMPLES/PRODUCTS RECEIVED UNDER THIS CONTRACT

      The contractor agrees that samples/products received from/through the
      Government for utilization under this contract shall be used only for
      purposes required to fulfill the Statement of Work and for no other
      purpose, specifically not for manufacturing or selling in conjunction with
      its parent company.

e.    CORRESPONDENCE PROCEDURES

      To promote timely and effective administration, correspondence (except
      for invoices, technical progress reports/other deliverables) submitted
       under this contract shall be subject to the following procedures:

      (1)   Technical correspondence shall be addressed to the Project Officer
            with an information copy of the basic correspondence to the
            Contracting Officer. (As used herein, technical correspondence
            EXCLUDES correspondence which proposes deviations from or
            modifications of contract requirements, terms or conditions)

      (2)   Other correspondence shall be addressed to the Contracting Officer,
            with an information copy of the basic correspondence to the Project
            Officer.

      (3)   Subject Line(s). All correspondence shall contain a subject line
            commencing with the contract number as illustrated below:

                  SUBJECT: Contract No. NO1-AI-95381
                              Request for Approval of

                                       5
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

g.    CONFIDENTIAL TREATMENT OF SENSITIVE INFORMATION

      The Contractor shall guarantee strict confidentiality of the
      information/data that is provided by the Government during the performance
      of the contract. The Government has determined that the information/data
      that the Contractor will be provided during the performance of the
      contract is of a sensitive nature and can not be disclosed in any matter.

      Disclosure of the information/data, in whole or in part, by the Contractor
      can only be made after the Contractor receives prior written approval from
      the Contracting Officer. Whenever the Contractor is uncertain with regard
      to the proper handling of information/data under the contract, the
      Contractor shall obtain a written determination from the Contracting
      Officer.

SECTION C - STATEMENT OF WORK

ARTICLE C.1.  STATEMENT OF WORK

a.    Independently and not as an agent of the Government, the Contractor shall
      furnish all the necessary services, qualified personnel, material,
      equipment, and facilities, not otherwise provided by the Government as
      needed to perform the Statement of Work SECTION J, ATTACHMENT 1 , dated
      August 16, 1999, attached hereto and made a part of this contract.

ARTICLE C.2.  REPORTING REQUIREMENTS

a.    TECHNICAL REPORTS

      In addition to those reports required by the other terms of this contract,
      the Contractor shall prepare and submit the following reports in the
      manner stated below and in accordance with ARTICLE F.1. DELIVERIES of this
      contract:

      1)    Quarterly Progress Reports

            By the fifteenth day of the month following the end of each quarter,
            the Contractor shall submit two (2) copies of a quarterly progress
            report as described below. The first reporting period shall consist
            of the first full three months of performance including any
            fractional part of the initial month (August 16, 1999 through
            November 30, 1999). One (1) copy shall be submitted to the Project
            Officer and one (1) copy to the Contracting Officer. A quarterly
            report is not due when an annual report is due. The quarterly report
            should be factual, concise, and consist of the following:

            a)    Title page containing:

                  (1) Contract number and title

                  (2) Sequence of report; (e.g., "Year 1, 2nd Quarterly Report")

                  (3) Period of performance being reported

                  (4) Contractor's name and address

                  (5) Date of submission

            b)    Reports shall include, but are not limited to the following
                  information:

                  (1) A brief introduction covering the objective and scope of
                      the contract effort.

                  (2) A description of the overall work accomplished during
                      the quarter plus brief descriptions of shipping activity
                      both into and out of the Repository, including specimen
                      disbursement requests.

                  (3) A description of any technical or performance problems
                      encountered and corrective actions planned or taken.

                                       6
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

                  (4) An explanation of any differences between planned and
                      actual progress.

                  (5) Selected other information as may be required by the
                      Project Officer.

      2)    Annual Progress Report

            Thirty (30) days after each anniversary date of the contract, the
            Contractor shall submit two (2) copies of an annual report. One (1)
            copy shall be submitted to the Project Officer and one (1) copy to
            the Contracting Officer. The annual report shall be factual and
            concise and summarize progress for the entire contract year,
            following the same format as for the Quarterly Progress Reports and
            shall take the place of the fourth Quarterly Progress Report each
            year. An annual report is not required when the final report is due.

      3)    Interim Reports

            Upon request by the Project Officer, and within five working days of
            such a request, the Contractor shall provide an interim report to
            cover the period of the current week or latest 1 - 4 weeks, and
            describing:

            a)    the specific work accomplished and in progress
            b)    a summary of all shipping activity into and out of the
                  Repository
            c)    a description of any technical or performance problems
                  encountered and corrective actions
                  planned or taken
            d)    estimated time taken to complete the work described
            e)    selected other items as required by the Project Officer

      4)    Final Report

            The contractor shall submit two (2) copies of the final report,
            which will summarize the results of the entire contract work for the
            complete performance period. One (1) copy shall be submitted to the
            Project Officer and one (1) copy to the Contracting Officer. This
            report will follow the same format as for the Annual Progress Report
            and shall take the place of the last Annual Progress Report. It
            shall be in sufficient detail to explain comprehensively the results
            achieved and shall be submitted no later than the completion date of
            the contract.

      5)    Other Deliverables

            a)    The Contractor shall prepare a transition plan within 30
                  calendar days of award date.
            b)    The Contractor shall prepare a User Manual of SOPs, subject
                  to Project Officer approval, for all aspects of specimen
                  handling within 45 calendar days of award date.
            c)    By February 1, 2000, the Contractor shall prepare (in
                  coordination with the Project Officer and other DAIDS cohorts)
                  a Repository Management Plan, subject to Project Officer
                  approval, which addresses issues of a proposed maximum
                  capacity that the DAIDS Specimen Repository should maintain;
                  criteria for determining which specimens are collected,
                  stored, or discarded for each research study;
                  availability/accessibility of specimens to the scientific
                  community; quality control; and specific steps to institute
                  the plan's targeted goals.
            d)    The Contractor, subject to Project Officer approval, shall
                  deliver to the Government or its designee the following items
                  by the completion date of the Contract:

                  (1)   Stored specimens including those received by the
                        Contractor from the Project Officer or designated
                        investigators.
                  (2)   A computer-generated listing of accurate and updated
                        information on specimen inventory, including activities
                        of the contractor, computerized data files, original
                        data, and any necessary information related thereto;
                  (3)   Labeled and inventoried paper files; and
                  (4)   Government-owned equipment and specimen property.

                                       7
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

b.    Delivery of Reports

      If the Contractor becomes unable to deliver the reports or other
      deliverables specified hereunder within the period of performance because
      of unforeseen difficulties, notwithstanding the exercise of good faith and
      diligent efforts in performance of the work, the Contractor shall give the
      Contracting Officer immediate written notice of anticipated delays with
      reasons therefore at the address given below.

      1)    Project Officer
            ETB, VPRP, DAIDS, NIAID, NIH
            6700-B Rockledge Drive, Room 4232, MSC 7628
            Bethesda, Maryland 20892-7628

      2)    Contracting Officer
            CMB, DEA, NIAID, NIH
            6700-B Rockledge Drive, Room 2230, MSC 7612
            Bethesda, Maryland 20892-7612

SECTION D - PACKAGING, MARKING AND SHIPPING

All Specimens under this contract shall be packaged, marked and shipped in
accordance with Government specifications. Specifically, shipping containers
must be used which comply with U.S. DOT or IATA regulations for infectious
substances, styrofoam boxes, liquid nitrogen shipping containers, labeling
material, shipping forms, and any other IATA requirements.

The contractor shall operate in accordance with the basic references and
other modifications by the Public Health Service which include but are not
limited to:

      (1)   Title 49 CFR Part 100-199 Transportation

      (2)   Title 42 CFR Part 71.54 and 72.3 Etiologic Agents, Hosts and
            Vectors; Interstate Shipment of Etiologic Agents

      (3)   Title 39 CFR Part 124 Postal Services

      (4)   International Air Transport Association (IATA), Dangerous Goods
            Regulations 36th Edition 1995, and 1997 changes to the IATA
            Dangerous Good Regulations

      (5)   International Civil Aviation Organization (ICAO) Technical
            Instructions for the Safe Transportation of Dangerous Good by Air
            1995-1996

      (6)   United Nations Recommendations on the Transport of Dangerous Good
            8th Edition

All other deliverables required under this contract shall be packaged, marked
and shipped in accordance with Government specifications. At a minimum, all
deliverables shall be marked with the contract number and name. The
Contractor shall guarantee that all required materials shall be delivered in
immediate usable and acceptable condition.

SECTION E - INSPECTION AND ACCEPTANCE

a     The Contracting Officer or the duly authorized representative will perform
      inspection and acceptance of materials and services to be provided.

b.    For the purpose of this ARTICLE the Project Officer is the authorized
      representative of the Contracting Officer.

c.    Inspection and acceptance will be performed at:

                              ETB, VPRP, DAIDS, NIAID, NIH

                                       8
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

                              6700-B Rockledge Drive, Room 4232, MSC 7628
                              Bethesda, Maryland 20892-7628

      Acceptance may be presumed unless otherwise indicated in writing by the
      Contracting Officer or the duly authorized representative within 30 days
      of receipt.

d.    This contract incorporates the following clause by reference, with the
      same force and effect as if it were given in full text. Upon request, the
      Contracting Officer will make its full text available.

      FAR Clause No. 52.246-5, INSPECTION OF SERVICES-COST REIMBURSEMENT
      (APRIL 1984).

SECTION F - DELIVERIES OR PERFORMANCE

ARTICLE F.1.  DELIVERIES

a.    Satisfactory performance of this contract shall be deemed to occur upon
      delivery and acceptance by the Contracting Officer, or the duly authorized
      representative, of the items specified in the Delivery Schedule which are
      described in SECTION C of this contract.

b.    Deliveries required by the contractor shall be made f.o.b. destination as
      set forth in FAR 52.247-35, F.O.B. DESTINATION, WITHIN CONSIGNEES PREMISES
      (APRIL 1984), and in accordance with and by the dates specified below:

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------
TYPE OF REPORT     NO OF COPIES           ADDRESS                             DUE DATES
--------------     ------------      -------------------------------     ----------------------------
<S>                <C>               <C>                                 <C>
Quarterly               1            Project Officer                     Beginning on December 15,
                                     VPRP, ETB, DAIDS                    1999, and quarterly
                                     NIAID, NIH                          thereafter.  A quarterly
                                     6700-B Rockledge Dr.                will not be due when
                                     Rm. 4232                            submitting an annual or
                                     Bethesda, MD 20892                  final report.
--------------     ------------      -------------------------------     ----------------------------
Quarterly               1            Contracting Officer                 Same as above
                   (Original)        NIH, NIAID, CMB
                                     6700-B Rockledge Dr.
                                     Rm. 2230, MSC 7612
                                     Bethesda, MD 20892-7612
--------------     ------------      -------------------------------     ----------------------------
Annual                  1            P.O.'s Address above                Beginning September 15,
                                                                         2000, and 30 days following
                                                                         each anniversary date of
                                                                         the contract thereafter.
--------------     ------------      -------------------------------     ----------------------------
Annual                  1            C.O.'s Address above                Same as above
                   (Original)
--------------     ------------      -------------------------------     ----------------------------
Final                   1            P.O.'s Address above                On/before August 15, 2006
--------------     ------------      -------------------------------     ----------------------------
Final                   1            C.O.'s Address above                Same as above
                   (Original)
------------------------------------ ----------------------------------- -----------------------------

</TABLE>

                                       9
<PAGE>

                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

ARTICLE F.2. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)

This contract incorporates the following clause by reference, with the same
force and effect as if it were given in full text. Upon request, the
Contracting Officer will make its full text available. Also, the full text of
a clause may be accessed electronically at this address:
http://www.arnet.gov/far/.

FEDERAL ACQUISITION REGULATION (48 CFR CHAPTER 1) CLAUSE:

      52.242-15, Stop Work Order (AUGUST 1989) with ALTERNATE I (APRIL 1984).

SECTION G - CONTRACT ADMINISTRATION DATA

ARTICLE G.1.  PROJECT OFFICER

The following Project Officer(s) will represent the Government for the
purpose of this contract:

                  Elaine Matzen, R.N., Health Specialist

The Project Officer is responsible for: (1) monitoring the Contractor's
technical progress, including the surveillance and assessment of performance
and recommending to the Contracting Officer changes in requirements; (2)
interpreting the Statement of Work and any other technical performance
requirements; (3) performing technical evaluation as required; (4) performing
technical inspections and acceptances required by this contract; and (5)
assisting in the resolution of technical problems encountered during
performance.

The Contracting Officer is the only person with authority to act as agent of
the Government under this contract. Only the Contracting Officer has
authority to: (1) direct or negotiate any changes in the Statement of Work;
(2) modify or extend the period of performance; (3) change the delivery
schedule; (4) authorize reimbursement to the Contractor any costs incurred
during the performance of this contract; or (5) otherwise change any terms
and conditions of this contract.

The Contracting Officer hereby delegates the Project Officer as the
Contracting Officer's authorized representative responsible for signing
software license agreements issued as a result of this contract.

The Government may unilaterally change its Project Officer designation.

ARTICLE G.2.  KEY PERSONNEL

The personnel specified in this contract are considered to be essential to
the work to be performed hereunder. Prior to diverting any of the specified
individuals to other programs, the Contractor shall notify the Contracting
Officer reasonably in advance and shall submit justification (including
proposed substitutions) in sufficient detail to permit evaluation of the
impact on the program. No diversion shall be made by the Contractor without
the written consent of the Contracting Officer; provided, that the
Contracting Officer may ratify in writing such diversion and such
ratification shall constitute the consent of the Contracting Officer required
by this article. The contract may be amended from time to time during the
course of the contract to either add or delete personnel, as appropriate.

The following individuals are considered to be essential to the work being
performed hereunder:

<TABLE>
<CAPTION>
                        NAME                                     TITLE
<S>                                                        <C>
            Mark Cosentino, Ph.D., D.P.M.                  Principal Investigator
            Carla Hanson                                   Co-Project Manager
            Kathi Shea                                     Co-Project Manager

</TABLE>

                                       10
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

<TABLE>
<S>                                                        <C>
            Jiuping (Jay) Ji, Ph.D.                        Co-Investigator
            Hanna Weissberger, Ph.D.                       Co-Investigator
</TABLE>

ARTICLE G.3. INVOICE SUBMISSION/CONTRACT FINANCING REQUEST AND CONTRACT
FINANCIAL REPORT

a.    Invoice/Financing Request Instructions and Contract Financial Reporting
      for NIH Cost-Reimbursement Type Contracts NIH(RC)-4 are attached and made
      part of this contract. The instructions and the following directions for
      the submission of invoices/financing request must be followed to meet the
      requirements of a "proper" payment request pursuant to FAR 32.9.

b.    These instructions also provide for the submission of financial and
      personnel reporting required by HHSAR 342.7002. Unless otherwise stated in
      that part of the Instructions for Completing Form NIH(RC)-4 (see
      ATTACHMENT 1), all columns A through H shall be completed for each invoice
      submitted.

c.    The Contracting Officer may require the Contractor to submit detailed
      support for costs contained in one or more interim financial invoices.
      This clause does not supersede the record retention requirements of FAR
      Part 4.7.

d.    The contractor agrees to provide a detailed breakdown on invoices of cost
      and personnel reporting and variances from the negotiated budget in the
      following cost categories:

      1)    Direct Labor - List individuals by name, title/position,
            hourly/annual rate, level of effort, and amount claimed.
      2)    Fringe Benefits - Cite rate and amount
      3)    Overhead - Cite rate and amount
      4)    Materials & Supplies - Include detailed breakdown when total amount
            is over $1,000.
      5)    Travel - Identify travelers, dates, destination, purpose of trip,
            and amount. Cite COA, if appropriate. List separately, domestic
            travel, general scientific meeting travel, and foreign travel.
      6)    Consultant Fees - Identify individuals and amounts.
      7)    Subcontracts - Attach subcontractor invoice(s).
      8)    Other Direct Costs - Provide breakdown when total amount is over
            $1,000.
      9)    Equipment - Cite authorization and amount.
      10)   G&A - Cite rate and amount.
      11)   Total Cost
      12)   Fixed Fee
      13)   Total Amount Claimed
      14)   Adjustments
      15)   Grand Totals

e.    Invoices must include the cumulative total expenses to date, adjusted (as
      applicable) to reflect any amounts suspended by the Government.

e.    THE CONTRACTOR AGREES TO IMMEDIATELY NOTIFY THE CONTRACTING OFFICER, IN
      WRITING, IF THERE IS AN ANTICIPATED OVERRUN (ANY AMOUNT) OR UNEXPENDED
      BALANCE (GREATER THAN 10 PERCENT) OF THE AMOUNT CURRENTLY ALLOTTED TO THE
      CONTRACT AND THE REASONS FOR THE VARIANCE. Also, refer to the requirements
      of FAR 52.232-20, Limitation of Cost, referenced in the contract.

f.    Invoices/financing requests shall be submitted in the form of an ORIGINAL
      AND TWO COPIES to the following designated BILLING office:

                   Contracting Officer
                   Contract Management Branch, DEA
                   National Institute of Allergy and Infectious Diseases, NIH
                   6700-B Rockledge Drive, Room 2230, MSC 7612

                                       11
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

                        Bethesda, Maryland  20892-7612

g.    Inquiries regarding approval of invoices should be directed to the
      designated BILLING office, (301) 496-0612.

h.    The Contractor shall include the following certification on every invoice
      for reimbursable costs incurred with Fiscal Year funds subject to the
      salary rate limitation provisions as specified in ARTICLE H.5. of this
      contract. For billing purposes, certified invoices are required for the
      billing period during which the applicable Fiscal Year funds were
      initially charged through the final billing period utilizing the
      applicable Fiscal Year funds:

            "I hereby certify that the salaries charged in this invoice are in
            compliance with the Public Law (P.L.) cited for the applicable
            Fiscal Year as stated in ARTICLE H.5. of the above referenced
            contract."

ARTICLE G.4.  INDIRECT COST RATES

In accordance with Federal Acquisition Regulation (FAR) (48 CFR Chapter 1)
Clause 52.216-7 (d)(2), Allowable Cost and Payment incorporated by reference in
this contract in Part II, Section I, the cognizant Contracting Officer
responsible for negotiating provisional and/or final indirect cost rates is
identified as follows:

            Director, Division of Financial Advisory Services
            Office of Contracts Management
            National Institutes of Health
            6100 Building, Room 6B05
            6100 EXECUTIVE BLVD MSC-7540
            BETHESDA MD 20892-7540

Please see Article B.4. Advance Understandings, paragraph b., Indirect Costs.
These rates are hereby incorporated without further action of the Contracting
Officer. The above information notwithstanding, the notification required to be
submitted to the Contracting Officer pursuant to FAR 52.232-22, "Limitation of
Funds," of this contract shall remain in effect.

ARTICLE G.5.  GOVERNMENT PROPERTY

a.    In addition to the requirements of the clause, GOVERNMENT PROPERTY,
      incorporated in Section I of this contract, the Contractor shall comply
      with the provisions of DHHS Publication, CONTRACTOR'S GUIDE FOR CONTROL OF
      GOVERNMENT PROPERTY, (1990), which is incorporated into this contract by
      reference. Among other issues, this publication provides a summary of the
      Contractor's responsibilities regarding purchasing authorizations and
      inventory and reporting requirements under the contract. A copy of this
      publication is available upon request to the Contract Property
      Administrator.

      This contract's Contract Property Administrator is:

            Charles Varga
            Contracts Property Administrator
            Research Contracts Property Administration, NIH
            6011Building, Room 641E
            6011 EXECUTIVE BLVE MSC 7670
            BETHESDA MD 20852-7670
            (301) 496-6466

                                       12
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

b.    CONTRACTOR-ACQUIRED GOVERNMENT PROPERTY - SCHEDULE I-A

      Pursuant to the clause, GOVERNMENT PROPERTY, incorporated in this
      contract, the Contractor is hereby authorized to acquire the property
      listed in Schedule I-A below for use in direct performance of the
      contract. Title of this property shall vest in the Government

                             SCHEDULE I-A - (Year 1)

<TABLE>
<CAPTION>
      Item No.    Quantity         Description                           Est. Cost
      --------    --------         -----------                           ---------
<S>               <C>        <C>                                        <C>
      1-15           15      -70 degrees freezers @ $7,550 each          $ 113,250
      16-19          4       LN2 freezers (XLC-1830) @ $20,450 each      $  81,800
      17             1       Racking System for LN2                      $   4,740
      18             1       Additional LN2 Vacuum Piping                $   9,500
      19-25          7       Racking System for -70c @ $3,388 each       $  23,716
      26-28          3       Bar Coding Scanner @ $1,300 each            $   3,900
      29-32          4       Computers @ $887 each                       $   3,548
      33             1       T1 Line for Computer System                 $   1,000
                                                                         ----------
                                         TOTAL                           $ 241,454

</TABLE>

c.    CONTRACTOR-ACQUIRED GOVERNMENT PROPERTY - SCHEDULE I-B

      Pursuant to the clause, GOVERNMENT PROPERTY, incorporated in this
      contract, the Contractor will be authorized to acquire the property listed
      in Schedule I-B for use in direct performance of the contract, following
      receipt of the Contracting Officer's written approval, based on
      contractor-furnished prices and evidence of competition.

                           SCHEDULE I-B -- (Years 2-7)

<TABLE>
<CAPTION>
     Description                   Yr.2         Yr.3         Yr.4        Yr.5        Yr.6         Yr.7      Total (Yrs. 2-7)
     -----------                   ----         ----         ----        ----        ----         ----      ----------------
<S>                              <C>          <C>          <C>         <C>         <C>          <C>         <C>
     -70(degree)freezer &        8 units      13 units     13 units    13 units    13 units     13 units       73 units
     racking system              $ 90,129     $147,259     $151,677    $156,228    $160,914     $165,741       $871,948

     LN2 freezer &               1 unit       2 units      1 unit      1 unit      1 unit       2 units        8 units
     racking system              $25,946      $53,447      $27,526     $28,352     $29,202      $60,157        $224,630

         Total                   $116,075     $200,706     $179,203    $184,580    $190,116     $225,898       $1,096,578
</TABLE>

d.   GOVERNMENT FURNISHED PROPERTY - SCHEDULE II-A

     Pursuant to the clause, GOVERNMENT PROPERTY, incorporated in this contract,
     the Contractor is hereby authorized to retain custody of the property
     listed in Attachment 5, Schedule II-A for use in direct performance of this
     contract. Accountability for the items listed in Schedule II-A is hereby
     transferred to this contract from predecessor Contract No. NO1-AI-45204 ,
     under which these items were provided by the Government. Title to this
     property shall remain in the Government.

                                       13
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

ARTICLE G.6. POST AWARD EVALUATION OF PAST PERFORMANCE

Interim and final evaluations of contractor performance will be prepared on
this contract in accordance with FAR 42.15. The final performance evaluation
will be prepared at the time of completion of work. In addition to the final
evaluation, interim evaluations will be prepared annually to coincide with
the anniversary date of the contract.

Interim and final evaluations will be provided to the Contractor as soon as
practicable after completion of the evaluation. The Contractor will be
permitted thirty days to review the document and to submit additional
information or a rebutting statement. Any disagreement between the parties
regarding an evaluation will be referred to an individual one level above the
Contracting Officer, whose decision will be final.

Copies of the evaluations, contractor responses, and review comments, if any,
will be retained as part of the contract file, and may be used to support
future award decisions.

SECTION H - SPECIAL CONTRACT REQUIREMENTS

ARTICLE H.1. REIMBURSEMENT OF COSTS FOR INDEPENDENT RESEARCH AND DEVELOPMENT
PROJECTS

The primary purpose of the Public Health Service (PHS) is to support and
advance independent research within the scientific community. This support is
provided in the form of contracts and grants totaling approximately 7 billion
dollars annually. PHS has established effective, time tested and well
recognized procedures for stimulating and supporting this independent
RESEARCH by selecting from multitudes of applications those research projects
most worthy of support within the constraints of its appropriations. The
reimbursement through the indirect cost mechanism of independent research and
development costs not incidental to product improvement would circumvent this
competitive process.

To ensure that all research and development projects receive similar and
equal consideration, all organizations may compete for direct funding of
independent research and development projects they consider worthy of support
by submitting those projects to the appropriate Public Health Service grant
office for review. Since these projects may be submitted for direct funding,
the Contractor agrees that no costs for any independent research and
development project, including all applicable indirect costs, will be claimed
under this contract.

ARTICLE H.2.  HUMAN SUBJECTS

It is hereby understood and agreed that research involving human subjects
shall not be conducted under this contract, and that no material developed,
modified, or delivered by or to the Government under this contract, or any
subsequent modification of such material, will be used by the Contractor or
made available by the Contractor for use by anyone other than the Government,
for experimental or therapeutic use involving humans without the prior
written approval of the Contracting Officer.

ARTICLE H.3. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH

a.    Pursuant to Public Law(s) cited in paragraph b. , below, NIH is prohibited
      from using appropriated funds to support human embryo research. Contract
      funds may not be used for (1) the creation of a human embryo or embryos
      for research purposes; or (2) research in which a human embryo or embryos
      are destroyed, discarded, or knowingly

                                       14
<PAGE>

      subjected to risk of injury or death greater than that allowed for
      research on fetuses in utero under 45 CFR 46.208(a)(2) and Section 498(b)
      of the Public Health Service Act (42 U.S.C. 289g(b)). The term "human
      embryo or embryos" includes any organism, not protected as a human
      subject under 45 CFR 46 as of the date of the enactment of this Act,
      that is derived by fertilization, parthenogenesis, cloning, or any
      other means from one or more human gametes or human diploid cells.

     Additionally, in accordance with a March 4, 1997 Presidential Memorandum,
     Federal funds may not be used for cloning of human beings.

<TABLE>
<CAPTION>
b.   PUBLIC LAW AND SECTION NO.         FISCAL YEAR           PERIOD COVERED
<S>                                     <C>                 <C>
         105-297, Section 511               1999             10/1/98 - 9/30/99
</TABLE>

ARTICLE H.4.  NEEDLE EXCHANGE

a.   Pursuant to Public Law(s) cited in paragraph b., below, contract funds
     shall not be used to carry out any program of distributing sterile needles
     or syringes for the hypodermic injection of any illegal drug.

<TABLE>
<CAPTION>
b.   PUBLIC LAW AND SECTION NO.         FISCAL YEAR           PERIOD COVERED
<S>                                     <C>                  <C>
         105-277, Section 505               1999             10/1/98 - 9/30/99
</TABLE>

ARTICLE H.5. SALARY RATE LIMITATION LEGISLATION PROVISIONS

a.   Pursuant to Public Law(s) cited in paragraph b., below, no NIH Fiscal Year
     funds for the applicable fiscal year(s) and periods cited in paragraph b.,
     below may be used to pay the direct salary of an individual through this
     contract at a rate in excess of applicable amount shown for the fiscal year
     and period covered. Direct salary is exclusive of overhead, fringe benefits
     and general and administrative expenses. The per year salary rate limit
     also applies to individuals proposed under subcontracts. If this is a
     multi-year contract, it may be subject to unilateral modifications by the
     Government if an individual's salary rate exceeds any salary rate ceiling
     established in future DHHS appropriation acts.

<TABLE>
<CAPTION>
                                                                  DOLLAR AMOUNT OF
b.   PUBLIC LAW NO.      FISCAL YEAR      PERIOD COVERED         SALARY LIMITATION
<S>                      <C>             <C>                     <C>
         105-277            1999         10/1/98 - 9/30/99          $125,900
</TABLE>

ARTICLE H.6. EPA ENERGY STAR REQUIREMENTS

In compliance with Executive Order 12845 (requiring Agencies to purchase
energy efficient computer equipment) all microcomputers, including personal
computers, monitors, and printers that are deliverables under the procurement
or are purchased by the contractor using Government funds in performance of a
contract shall be equipped with or meet the energy efficient low-power
standby feature as defined by the EPA Energy Star program unless the
equipment always meets EPA Energy Star efficiency levels. The microcomputer,
as configured with all components, must be Energy Star compliant.

This low-power feature must already be activated when the computer equipment
is delivered to the agency and be of equivalent functionality of similar
power managed models. If the equipment will be used on a local area network,
the vendor must provide equipment that is fully compatible with the network
environment. In addition, the equipment will run commercial off-the-shelf
software both before and after recovery from its energy conservation mode.

                                       15
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

ARTICLE H.7.  PUBLICATION AND PUBLICITY

The contractor shall acknowledge the support of the National Institutes of
Health whenever publicizing the work under this contract in any media by
including an acknowledgment substantially as follows:

     "This project has been funded in whole or in part with Federal funds from
     the National Institute of Allergy and Infectious Diseases, National
     Institutes of Health, under Contract No. NO1-AI-95381."

ARTICLE H.8.  PRESS RELEASES

a.   Pursuant to Public Law(s) cited in paragraph b., below, the contractor
     shall clearly state, when issuing statements, press releases, requests for
     proposals, bid solicitations and other documents describing projects or
     programs funded in whole or in part with Federal money: (1) the percentage
     of the total costs of the program or project which will be financed with
     Federal money; (2) the dollar amount of Federal funds for the project or
     program; and (3) the percentage and dollar amount of the total costs of the
     project or program that will be financed by nongovernmental sources.

<TABLE>
<CAPTION>
b.   PUBLIC LAW AND SECTION NO.         FISCAL YEAR         PERIOD COVERED
<S>                                     <C>                <C>
         105-277, Section 507              1999            10/1/98-9/30/99
</TABLE>

ARTICLE H.9. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

Anyone who becomes aware of the existence or apparent existence of fraud,
waste and abuse in NIH funded programs is encouraged to report such matters
to the HHS Inspector General's Office in writing or on the Inspector
General's Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477).
All telephone calls will be handled confidentially. The e-mail address is
HTIPS@OS.DHHS.GOV and the mailing address is:

         Office of Inspector General
         Department of Health and Human Services
         TIPS HOTLINE
         P.O. Box 23489
         Washington, D.C.  20026

Information regarding procedural matters is contained in the NIH Manual
Chapter 1754, which is available on (http://www1.od.nih.gov/oma/oma.htm)

ARTICLE H.10. YEAR 2000 COMPLIANCEARTICLE H.10. YEAR 2000 COMPLIANCE

In accordance with FAR 39.106, Information Technology acquired under this
contract must be Year 2000 compliant as set forth in the following clause(s):

1.   SERVICE INVOLVING THE USE OF INFORMATION TECHNOLOGY

     YEAR 2000 COMPLIANCE--SERVICE INVOLVING THE USE OF INFORMATION TECHNOLOGY

     The Contractor agrees that each item of hardware, software, and firmware
     used under this contract shall be able to accurately process date data
     (including, but not limited to, calculating, comparing and sequencing)
     from, into and between the twentieth and twenty-first centuries and the
     Year 1999 and the Year 2000 and leap year calculations.

                                 (End of Clause)

                                       16
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

2.   NONCOMMERCIAL SUPPLY ITEMS WARRANTY

     YEAR 2000 WARRANTY--NONCOMMERCIAL SUPPLY ITEMS

     The contractor warrants that each noncommercial item of hardware, software,
     and firmware delivered or developed under this contract and listed below
     shall be able to accurately process date data (including, but not limited
     to, calculating, comparing and sequencing) from, into and between the
     twentieth and twenty-first centuries and the Year 1999 and the Year 2000
     and leap year calculations, when used in accordance with the item
     documentation provided by the contractor, provided that all listed or
     unlisted items (e.g., hardware, software and firmware) used in combination
     with such listed item properly exchange date data with it. If the contract
     requires that specific listed items must perform as a system in accordance
     with the foregoing warranty, then that warranty shall apply to those listed
     items as a system. The duration of this warranty and the remedies available
     to the Government for breach of this warranty shall be as defined in, and
     subject to, the terms and limitations of any general warranty provisions of
     this contract provided that notwithstanding any provision to the contrary
     in such warranty provision(s), or in the absence of any such warranty
     provision(s), the remedies available to the Government under this warranty
     shall include repair or replacement of any listed item whose noncompliance
     is discovered and made known to the contractor in writing within ninety
     (90) days after acceptance. Nothing in this warranty shall be construed to
     limit any rights or remedies the Government may otherwise have under this
     contract with respect to defects other than Year 2000 performance.

                            YEAR 2000 COMPLIANT ITEMS
          Any database or software programs developed under this contract.
          ----------------------------------------------------------------

          ----------------------------------------------------------------

          ----------------------------------------------------------------
                                 (end of clause)

3.   COMMERCIAL SUPPLY PRODUCTS WARRANTY

     YEAR 2000 WARRANTY--COMMERCIAL SUPPLY ITEMS

     The contractor warrants that each hardware, software and firmware product
     delivered under this contract and listed below shall be able to accurately
     process date data (including, but not limited to, calculating, comparing,
     and sequencing) from, into, and between the twentieth and twenty-first
     centuries and the Year 1999 and the Year 2000 and leap year calculations,
     when used in accordance with the product documentation provided by the
     contractor, provided that all listed or unlisted products (e.g., hardware,
     software, firmware) used in combination with such listed product properly
     exchange date data with it. If the contract requires that specific listed
     products must perform as a system in accordance with the foregoing
     warranty, then that warranty shall apply to those listed products as a
     system. The duration of this warranty and the remedies available to the
     Government for breach of this warranty shall be as defined in, and subject
     to, the terms and limitations of the contractor's standard commercial
     warranty or warranties contained in this contract, provided that
     notwithstanding any provision to the contrary in such commercial warranty
     or warranties, the remedies available to the Government under this warranty
     shall include repair or replacement of any listed product whose
     non-compliance is discovered and made known to the contractor in writing
     within ninety (90) days after acceptance. Nothing in this warranty shall be
     construed to limit any rights or remedies the Government may otherwise have
     under this contract with respect to defects other than Year 2000
     performance.

                               YEAR 2000 COMPLIANT ITEMS ANY
            Database or software programs developed under this contract.
          ----------------------------------------------------------------

          ----------------------------------------------------------------

          ----------------------------------------------------------------
                                 (end of clause)

                                       17
<PAGE>
                                                          CONTRACT NO1-A1-95381
                                      BBI - BIOTECH RESEARCH LABORATORIES, INC.

                          PART II - CONTRACT CLAUSES

                          SECTION I - CONTRACT CLAUSES

ARTICLE I.1. GENERAL CLAUSES FOR A COST-REIMBURSEMENT SERVICE CONTRACT - FAR
52.252-2, CLAUSES INCORPORATED BY REFERENCE (FEBRUARY 1998)

This contract incorporates the following clauses by reference, with the same
force and effect as if they were given in full text. Upon request, the
Contracting Officer will make their full text available. Also, the full text
of a clause may be accessed electronically at this address:
http://www.arnet.gov/far/.

a.   FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

<TABLE>
<CAPTION>
 FAR CLAUSE
    NO.          DATE          TITLE
-----------    ---------       -----
<S>            <C>             <C>
 52.202-1      Oct 1995        Definitions

 52.203-3      Apr 1984        Gratuities (Over $100,000)

 52.203-5      Apr 1984        Covenant Against Contingent Fees (Over $100,000)

 52.203-6      Jul 1995        Restrictions on Subcontractor Sales to the Government (Over $100,000)

 52.203-7      Jul 1995        Anti-Kickback Procedures(Over $100,000)

 52.203-8      Jan 1997        Cancellation, Recission, and Recovery of Funds for Illegal or Improper Activity (Over
                               $100,000)
 52.203-10     Jan 1997        Price or Fee Adjustment for Illegal or Improper Activity (Over $100,000)

 52.203-12     Jun 1997        Limitation on Payments to Influence Certain Federal Transactions (Over $100,000)

 52.204-4      Jun 1996        Printing/Copying Double-Sided on Recycled Paper (Over $100,000)

 52.209-6      Jul 1995        Protecting the Government's Interests When Subcontracting With Contractors Debarred,
                               Suspended, or Proposed for Debarment (Over $25,000)

 52.215-2      Jun 1999        Audit and Records - Negotiation (Over $100,000)

 52.215-8      Oct 1997        Order of Precedence - Uniform Contract Format

 52.215-10     Oct 1997        Price Reduction for Defective Cost or Pricing Data

 52.215-12     Oct 1997        Subcontractor Cost or Pricing Data (Over $500,000)

 52.215-14     Oct 1997        Integrity of Unit Prices (Over $100,000)

</TABLE>

                                 18
<PAGE>
                                                    CONTRACT NO1-A1-95381
                                BBI - BIOTECH RESEARCH LABORATORIES, INC.

<TABLE>
<CAPTION>
 FAR CLAUSE
    NO.          DATE          TITLE
-----------    ---------       -----
<S>            <C>             <C>
 52.215-15     Dec 1998        Pension Adjustments and Asset Reversions

 52.215-18     Oct 1997        Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than
                               Pensions

 52.215-19     Oct 1997        Notification of Ownership Changes

 52.215-21     Oct 1997        Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data
                               - Modifications

 52.216-7      Apr 1998        Allowable Cost and Payment

 52.216-8      Mar 1997        Fixed Fee

 52.219-8      Jun 1999        Utilization of Small Business Concerns (Over $100,000)

 52.219-9      Jan 1999        Small Business Subcontracting Plan (Over $500,000)

 52.219-16     Jan 1999        Liquidated Damages - Subcontracting Plan (Over $500,000)

 52.222-2      Jul 1990        Payment for Overtime Premium (Over $100,000) (Note: The dollar amount in paragraph
                               (a) of this clause is $0 unless otherwise specified in the contract.)

 52.222-3      Aug 1996        Convict Labor

 52.222-26     Feb 1999        Equal Opportunity

 52.222-35     Apr 1998        Affirmative Action for Disabled Veterans and Veterans of the Vietnam Era

 52.222-36     Jun 1998        Affirmative Action for Workers with Disabilities

 52.222-37     Jan 1999        Employment Reports on Disabled Veterans and Veterans of  the Vietnam Era

 52.223-2      Apr 1984        Clean Air and Water (Over $100,000)

 52.223-6      Jan 1997        Drug-Free Workplace

 52.223-14     Oct 1996        Toxic Chemical Release Reporting

 52.225-11     Aug 1998        Restrictions on Certain Foreign Purchases

 52.227-1      Jul 1995        Authorization and Consent

 52.227-2      Aug 1996        Notice and Assistance Regarding Patent and Copyright Infringement (Over $100,000)

 52.227-3      Apr 1984        Patent Indemnity

 52.227-14     Jun 1987        Rights in Data - General

 52.232-9      Apr 1984        Limitation on Withholding of Payments

 52.232-17     Jun 1996        Interest (Over $100,000)

 52.232-20     Apr 1984        Limitation of Cost

 52.232-23     Jan 1986        Assignment of Claims

 52.232-25     Jun 1997        Prompt Payment

</TABLE>

                                       19
<PAGE>
                                                    CONTRACT NO1-A1-95381
                                BBI - BIOTECH RESEARCH LABORATORIES, INC.

<TABLE>
<CAPTION>
 FAR CLAUSE
    NO.          DATE          TITLE
-----------    ---------       -----
<S>            <C>             <C>
 52.232-34     May 1999        Payment by Electronic Funds Transfer--Other Than Central Contractor Registration

 52.233-1      Dec 1998        Disputes

 52.233-3      Aug 1996        Protest After Award, Alternate I (Jun 1985)

 52.242-1      Apr 1984        Notice of Intent to Disallow Costs

 52.242-3      Oct 1995        Penalties for Unallowable Costs (Over $500,000)

 52.242-4      Jan 1997        Certification of Final Indirect Costs

 52.242-13     Jul 1995        Bankruptcy (Over $100,000)

 52.243-2      Aug 1987        Changes - Cost Reimbursement, Alternate I (Apr 1984)

 52.244-2      Aug 1998        Subcontracts, Alternate II (Aug 1998) *If written consent to subcontract is required,
                               the identified subcontracts are listed in ARTICLE B, Advance Understandings.

 52.244-5      Dec 1996        Competition in Subcontracting (Over $100,000)

 52.245-5      Jan 1986        Government Property (Cost-Reimbursement, Time and Material, or Labor-Hour Contract)

 52.246-25     Feb 1997        Limitation of Liability - Services (Over $100,000)

 52.249-6      Sep 1996        Termination (Cost-Reimbursement)

 52.249-14     Apr 1984        Excusable Delays

 52.253-1      Jan 1991        Computer Generated Forms

</TABLE>

b.   DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR)
     (48 CFR CHAPTER 3) CLAUSES:

<TABLE>
<CAPTION>
  HHSAR
 CLAUSE NO.      DATE          TITLE
-----------    ---------       -----
<S>            <C>             <C>
 352.202-1     Apr 1984        Definitions - Alternate I (Apr 1984)

 352.228-7     Dec 1991        Insurance - Liability to Third Persons

 352.232-9     Apr 1984        Withholding of Contract Payments

 352.233-70    Apr 1984        Litigation and Claims

 352.242-71    Apr 1984        Final Decisions on Audit Findings

 352.270-5     Apr 1984        Key Personnel

 352.270-6     Jul 1991        Publication and Publicity

 352.270-7     Apr 1984        Paperwork Reduction Act

</TABLE>

            [End of GENERAL CLAUSES FOR A COST-REIMBURSEMENT SERVICE
                            CONTRACT - Rev. 7/1999].

                                       20
<PAGE>
                                                    CONTRACT NO1-A1-95381
                                BBI - BIOTECH RESEARCH LABORATORIES, INC.

ARTICLE I.2 AUTHORIZED SUBSTITUTION OF CLAUSES

ARTICLE I.1. of this SECTION is hereby modified as follows:

FAR Clause 52.219-9, SMALL BUSINESS SUBCONTRACTING PLAN (JANUARY 1999), and
FAR Clause 52.219-16, LIQUIDATED DAMAGES--SUBCONTRACTING PLAN (JANUARY 1999)
are deleted in their entirety.

FAR Clause 52.225-3, BUY AMERICAN ACT - SUPPLIES (JANUARY 1994) is deleted in
its entirety and FAR Clause 52.225-7 BALANCE OF PAYMENTS PROGRAM (APRIL 1984)
is substituted therefor.

FAR Clause 52.232-20, LIMITATION OF COST, is deleted in its entirety and FAR
Clause 52.232-22, LIMITATION OF FUNDS (APRIL 1984) is substituted therefor.

FAR Clause 52.243-1, CHANGES, FIXED PRICE, ALTERNATE I (AUGUST 1987) is
hereby deleted in its entirety and FAR Clause 52.243-1, CHANGES, FIXED PRICE,
ALTERNATE II (AUGUST 1987) is substituted therefor.

ARTICLE I.3. ADDITIONAL CONTRACT CLAUSES

This contract incorporates the following clauses by reference, with the same
force and effect, as if they were given in full text. Upon request, the
contracting officer will make their full text available.

a.    FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES

      (1)   FAR 52.215-17, Waiver of Facilities Capital Cost of Money
            (OCTOBER 1997).
      (2)   FAR 52.219-6, Notice of Total Small Business Set-Aside (JULY 1996).
      (3)   FAR 52.219-14, Limitation on Subcontracting (DECEMBER 1996).
      (4)   FAR 52.223-3, Hazardous Material Identification and Material Safety
            Data (JANUARY 1997), ALTERNATE I (JULY 1995).
      (5)   FAR 52.223-11, Ozone-Depleting Substances (JUNE 1996).
      (6)   FAR 52.223-12, Refrigeration Equipment and Air Conditioners
            (MAY 1995).
      (7)   FAR 52.237-3, Continuity of Services (JANUARY 1991).
      (8)   FAR 52.245-19, Government Property Furnished "As Is" (APRIL 1984).
      (9)   FAR 52.247-63, Preference for U.S. Flag Air Carriers (JANUARY 1997).
      (10)  FAR 52.247-64, Preference for Privately Owned U.S. Flag Commercial
            Vessels (JUNE 1997).
      (11)  FAR 52.251-1, Government Supply Sources (APRIL 1984).

b.    DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION/PUBLIC
      HEALTH SERVICE ACQUISITION REGULATION (HHSAR)/(PHSAR) (48 CHAPTER 3)
      CLAUSES:

      (1)   PHS 352.223-70, Safety and Health (Deviation) (AUGUST 1997).

                                       21
<PAGE>
                                                    CONTRACT NO1-A1-95381
                                BBI - BIOTECH RESEARCH LABORATORIES, INC.

      (2)   HHSAR 352.224-70, Confidentiality of Information (APRIL 1984).

c. NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH CONTRACTING (RC) CLAUSES:

      The following clauses are attached and made a part of this contract:

      (1)   NIH (RC)-7, Procurement of Certain Equipment (APRIL 1984) (OMB
            Bulletin 81-16).

ARTICLE I.4. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

This contract incorporates the following clauses in full text.

FEDERAL ACQUISITION REGULATION (FAR)(48 CFR CHAPTER 1) CLAUSES:

a.    FAR CLAUSE 52.225-9, TRADE AGREEMENTS ACT (DEVIATION)

      (a)   This clause implements the Trade Agreements Act of 1979 (19 U.S.C.
            2501-2582) by providing a preference for U.S. made end products,
            North American Free Trade Agreement (NAFTA) country end products,
            designated country end products, and Caribbean Basin country end
            products over other products.

            "CARIBBEAN BASIN COUNTRY END PRODUCTS," as used in this clause,
            means an article that: (1) is wholly the growth, product, or
            manufacture of a Caribbean Basin country (as defined in section
            25.401 of the Federal Acquisition Regulation (FAR), or (2) in the
            case of an article which consists in whole or in part of materials
            from another country or instrumentality, has been substantially
            transformed into a new and different article of commerce with a
            name, character, or use distinct from that of the article or
            articles from which it was so transformed. The term refers to a
            product, offered for purchase under a supply contract, but for
            purposes of calculating the value of the end product includes
            services (except transportation services) incidental to its supply;
            provided that the value of those incidental services does not exceed
            that of the product itself. The term excludes products that are
            excluded from duty-free treatment for Caribbean countries under the
            Caribbean Basin Economic Recovery Act (19 U.S.C. 2703(b)). These
            exclusions presently consist of (I) textiles and apparel articles
            that are subject to textile agreements; (ii) footwear, handbags,
            luggage, flat goods, work gloves, and leather wearing apparel not
            designated as eligible articles for the purpose of the Generalized
            System of Preferences under title V of the Trade Act of 1974; (iii)
            tuna, prepared or preserved in any manner in airtight containers;
            (iv) petroleum; and (v) watches and watch parts (including cases,
            bracelets and straps) of whatever type including, but not limited
            to, mechanical, quartz digital or quartz analog, if such watches or
            watch parts contain any material that is the product of any country
            to which the Tariff Schedule of the United States (TSUS) column 2
            rates of duty apply.

            "DESIGNATED COUNTRY END PRODUCT," as used in this clause, means an
            article that (1) is wholly the growth, product, or manufacture of
            the designated country (as defined in section 25.401 of the Federal
            Acquisition Regulation (FAR), or (2) in the case of an article which
            consists in whole or in part of materials from another country or
            instrumentality, has been substantially transformed into a new and
            different article of commerce with a name, character, or use
            distinct from that of the article or articles from which it was so
            transformed. The term refers to a product offered for purchase under
            a supply contract, but for purposes of calculating the value of the
            end product includes services (except transportation services)
            incidental to its supply; provided that the value of those
            incidental services does not exceed that of the product itself.

            "ELIGIBLE PRODUCT," as used in this clause, means a designated,
            North American Free Trade Agreement (NAFTA), or Caribbean Basin
            country end product.

                                       22
<PAGE>
                                                    CONTRACT NO1-A1-95381
                                BBI - BIOTECH RESEARCH LABORATORIES, INC.

            "END PRODUCTS," as used in this clause, means those articles,
            materials, and supplies to be acquired under this contract for
            public use.

            "NAFTA COUNTRY END PRODUCT," as used in this clause, means an
            article that (1) is wholly the growth, product, or manufacture of a
            NAFTA country, or (2) in the case of an article which consists in
            whole or in part of materials from another country or
            instrumentality, has been substantially transformed in a NAFTA
            country into a new and different article of commerce with a name,
            character, or use distinct from that of the article or articles from
            which it was transformed. The term refers to a product offered for
            purchase under a supply contract, but for purposes of calculating
            the value of the end product includes services (except
            transportation services) incidental to its supply; provided, that
            the value of those incidental services does not exceed that of the
            product itself.

            "U.S. MADE END PRODUCT" as used in this clause, means an article
            which (1) is wholly the growth, product or manufacture of the United
            States, or (2) in the case of an article which consists in whole or
            in part of materials from another country or instrumentality, has
            been substantially transformed in the United States into a new and
            different article of commerce with a name, character, or use
            distinct from that of the article or articles from which it was so
            transformed.

            "NONDESIGNATED COUNTRY END PRODUCTS," as used in this clause, means
            any end product which is not a U.S. made end product or a designated
            country end product.

            "UNITED STATES," as used in this clause, means the United States,
            its possessions, Puerto Rico, and any other place which is subject
            to its jurisdiction, but does not include leased bases or trust
            territories.

      (b)   The Contractor agrees to deliver under this contract only U.S. made
            end products, designated country end products, Caribbean Basin
            country end products, or, if a national interest waiver is granted
            under section 302 of the Trade Agreements Act of 1979, nondesignated
            country end products. Only if such waiver is granted may a
            nondesignated country end product be delivered under this contract.

      (c)   Offers will be evaluated in accordance with the policies and
            procedures of Part 25 of the FAR except that offers of U.S. made end
            products shall be evaluated without the restrictions of the Buy
            American Act or Balance of Payments Program.

b.    FAR CLAUSE 52.244-6, SUBCONTRACTS FOR COMMERCIAL ITEMS AND COMMERCIAL
      COMPONENTS (OCTOBER 1998)

      (a)   Definition.

            Commercial item, as used in this clause, has the meaning contained
            in the clause at 52.202-1, Definitions.

            Subcontract, as used in this clause, includes a transfer of
            commercial items between divisions, subsidiaries, or affiliates of
            the Contractor or subcontractor at any tier.

      (b)   To the maximum extent practicable, the Contractor shall incorporate,
            and require its subcontractors at all tiers to incorporate,
            commercial items or nondevelopmental items as components of items to
            be supplied under this contract.
      (c)   Notwithstanding any other clause of this contract, the Contractor is
            not required to include any FAR provision or clause, other than
            those listed below to the extent they are applicable and as may be
            required to establish the reasonableness of prices under Part 15, in
            a subcontract at any tier for commercial items or commercial
            components:

            (1)   52.222-26, Equal Opportunity (E.O. 11246);
            (2)   52.222-35, Affirmative Action for Disabled Veterans and
                  Veterans of the Vietnam Era (38 U.S.C.

                                       23
<PAGE>
                                                    CONTRACT NO1-A1-95381
                                BBI - BIOTECH RESEARCH LABORATORIES, INC.

                  4212(a));
            (3)   52.222-36, Affirmative Action for Workers with Disabilities
                  (29 U.S.C. 793); and
            (4)   52.247-64, Preference for Privately Owned U.S.-Flagged
                  Commercial Vessels (46 U.S.C. 1241) (flow down not required
                  for subcontracts awarded beginning May 1, 1996).

      (d)   The Contractor shall include the terms of this clause, including
            this paragraph (d), in subcontracts awarded under this contract.

                                PART III

SECTION J - LIST OF ATTACHMENTS

The following documents are attached and incorporated in this contract:

      1)    Statement of Work, (8/16/99).
      2)    Invoice/Financing Request and Financial Reporting Instructions for
            NIH Cost-Reimbursement Type Contracts, NIH(RC)-4, (5/97).
      3)    Safety and Health (Deviation), PHSAR Clause 352.223-70, (8/97).
      4)    Procurement of Certain Equipment, NIH(RC)-7, (4/1/84).
      5)    Government Property - Schedule II-A, (8/16/99).

                                 PART IV

SECTION K - REPRESENTATIONS AND CERTIFICATIONS

The following documents are incorporated by reference in this contract:

      Representations and Certifications, dated November 6, 1998.

                               END OF THE SCHEDULE
                                   (CONTRACT)

                                       24
<PAGE>

                                 WORK STATEMENT
                      DIVISION OF AIDS SPECIMEN REPOSITORY

Independently, and not as an agent of the Government, the contractor shall
furnish services, qualified professional and technical personnel, material,
equipment, and facilities not otherwise provided by the Government under the
terms of this contract to perform the work set forth below.

In general, the Contractor shall: (1) secure, receive, catalog, process,
store, and disburse clinical specimens from human immunodeficiency virus
(HIV)-infected patients, cohort participants, recipients of candidate HIV
vaccines and other biomedical interventions in studies sponsored by the
National Institute of Allergy and Infectious Diseases (NIAID), Division of
AIDS (DAIDS); (2) provide a computerized specimen inventory management system
in a format identified and approved by DAIDS; (3) provide adequate
cold-storage facilities for clinical specimens, and provide experienced
professional personnel (formally trained in dangerous goods biosafety) to
support specimen handling and repository management; (4) provide labeling and
shipping procedure training and oversight to study sites; (5) report progress
to the Project Officer and provide specimen availability summaries as
requested by the Project Officer; (6) complete the development and the
execution of a DAIDS Repository Management Plan which may include, but is not
limited to: systematic effort to discard identified specimens with low
research potential, reduce the numbers of duplicate specimens, discard
specimens with missing key clinical data, and/or expand the freezer capacity
of the repository as requested by the Project Officer; and (7) ensure an
orderly and safe transition of the Repository from the incumbent Contractor,
and to a successor contractor, if necessary. Transition to a successor
contractor shall include all Repository data including all source codes.

Specifically, the Contractor shall:

1.    Secure, receive, process as necessary, catalog, store and ship clinical
      specimens to and from both domestic and international DAIDS study sites,
      and distribute clinical specimens to other investigators at the request of
      the Project Officer. Currently the specimen repository supports these
      DAIDS studies: MACS, WITS, WIHS, HIVNET, AACTG, PACTG, AVEG, DATRI, and
      maintains specimens from other completed DAIDS studies such as the Jump
      Start Project, the HATS, and the San Francisco Men's Health Study. These
      specimens may include, but are not limited to, peripheral blood
      mononuclear cells, serum, plasma, tissue specimens, and other bodily
      fluids or substances such as cervical-vaginal lavage (CVL), breast milk,
      semen, saliva, urine, feces, mucosal, autopsy and biopsy materials, and
      specimen spots dried on filter paper.

      A.    Advise investigators from study sites on procedures required for
            maintaining proper specimen temperature and ensuring specimen
            identification in the shipment of samples; provide appropriate
            packaging material (e.g., shipping containers which comply with U.S.
            DOT or IATA regulations for infectious substances, styrofoam boxes,
            liquid nitrogen shipping containers, labeling material, shipping
            forms, etc.) to maintain appropriate environmental safeguards and
            desired refrigeration levels for specific specimens in transit;
            provide concise shipping instructions appropriate to the types of
            specimens and packaging materials; and cover costs for all shipments
            to the Repository. (See section 4 for information on training the
            study sites in the above procedures.) All shipments shall be
            coordinated by the Contractor to preserve sample integrity and
            utility. The contractor shall operate in accordance with the basic
            references and other modifications by the Public Health Service
            which include but are not limited to:

            (1)   Title 49 CFR Part 100-199 Transportation
            (2)   Title 42 CFR Part 71.54 and 72.3 Etiologic Agents, Hosts and
                  Vectors; Interstate Shipment of Etiologic Agents

Statement of Work (N01-AI-95381)                                  ATTACHMENT 1
08/16/99                                                           Page 1 of 3
<PAGE>

            (3)   Title 39 CFR Part 124 Postal Services
            (4)   International Air Transport Association (IATA), Dangerous
                  Goods Regulations 36th Edition 1995, and 1997 changes to the
                  IATA Dangerous Good Regulations
            (5)   International Civil Aviation Organization (ICAO) Technical
                  Instructions for the Safe Transportation of Dangerous Good by
                  Air 1995-1996
            (6)   United Nations Recommendations on the Transport of Dangerous
                  Good 8th Edition

      B.    Arrange for the shipping of specimens to the repository from all
            designated Domestic study sites WITHIN 24 HOURS of pickup and by
            overnight express shipment. Assist the NIAID in efforts to establish
            SOPs/guidelines for shipping of specimens to the repository from
            International study sites. This service shall be performed by an
            established carrier with a proven record for handling
            medical/clinical specimens on dry ice and in liquid nitrogen
            shipping container. Obtain appropriate shipping licenses and permits
            from local, state, Federal and international authorities for the
            safe import, storage and distribution of biohazardous materials.

      C.    Provide protective garments, equipment, and supplies to conduct work
            in Biosafety Level 2 containment facilities under aseptic and/or
            sterile conditions as appropriate and in accordance with all
            applicable Federal, state, and local laws, codes, ordinances, and
            regulations. It is expected that the contractor will operate in
            accordance with the following basic references and other related
            modifications by the Public Health Service, which include but are
            not limited to:

            (1)   Title 29 CFR 1910.1030 OSHA Bloodborne Pathogen Standard

            (2)   Health & Safety Guidelines for Grantees and Contractors, NIH
                  Guide, Vol. 24, No. 33, dated September 22, 1995

            (3)   Biosafety in the Laboratory: Prudent Practices for Handling
                  and Disposal of Infectious Materials; National Academy Press,
                  Wash., D.C.

            (4)   Biosafety in Microbiological and Biomedical Laboratories, U.S.
                  Department of Health and Human Services, Centers for Disease
                  Control and Prevention and National Institutes of Health, HHS
                  Pub. No. (CDC) 93-8395 published by the U.S. Government
                  Printing Office. (Website:
                  WWW.NIEHS.NIH.GOV/ODHSB/BIOSAFE/BMBL/BMBL-1.HTM)

            (5)   Recommendations for Prevention of HIV transmission in Health
                  Care Settings, Morbidity and Mortality Weekly Report, Vol. 36,
                  No. 2-S, dated August 21, 1987.

            (6)   Agent Summary Statement for Human Immunodeficiency Virus and
                  Report on Laboratory-Acquired Infection with Human
                  Immunodeficiency virus, Morbidity and Mortality Weekly Report,
                  Vol. 37, No.S-4, pp. 1-22, dated April 1, 1988.

      D.    Receive, catalog, process, and store incoming samples according to
            Standard Operating Procedures approved by the Project Officer, which
            shall include but not be limited to a 15% random inspection of tubes
            within each freezer box received, and a detailed quality assurance
            plan for ascertaining sample and shipment condition, validation of
            key information, criteria for specimen rejection, and guidelines for
            handling leaking or broken specimens. All problems and corrective
            action for each shipment shall be discussed with the Project Officer
            and study site staff and documented within 3 days of shipment
            receipt,

Statement of Work (N01-AI-95381)                                  ATTACHMENT 1
08/16/99                                                           Page 2 of 3

<PAGE>

            and noted in the Quarterly Progress Reports. Pertinent information
            (such as originating site, specimen number, quantity, shipping date,
            and/or other information as required) shall be maintained in the
            Specimen Inventory System. (See number 2 in this attachment for
            details.) The contractor shall support NIAID's efforts in the
            design, certification, and subsequent periodic re-certification
            of government-sponsored and owned DOD or commercial shipping
            containers for use under this contract.

      E.    Retrieve specimens from the repository; prepare aliquots, when
            necessary; disburse samples to national and/or international
            destinations upon specific written authorization from the Project
            Officer; provide for the return shipment of unused specimen portions
            and empty shipping containers and packing materials. Costs
            associated with such shipments are the responsibility of the
            Repository Contractor. Pertinent information (such as "shipped to"
            code, specimen number, quantity, shipping date, and/or other
            information as required) shall be maintained using the Specimen
            Inventory system. (See section 2.B for details.) Mention of these
            requests and resulting action shall be detailed in the Quarterly
            Progress Report.

      F.    Upon direction of the Project Officer, provide technical support to
            DAIDS staff in the practical application and execution in continuing
            the development and implementation of a Repository Management Plan
            (as noted below) (see Appendix for additional info).

2.    Provide and maintain a computer facility and Specimen Inventory Database
      Management System to track samples and activities in the Repository. This
      system shall be adaptable/programmable to include the capability to print
      and scan specimen labels that are bar-coded. (Approximately 4% of all
      Repository specimens stored/disbursed currently are bar-coded.)

      A.    Provide for the security of the Specimen Inventory Database with
            confidential access codes. The Project Officer will determine the
            level of information to be disseminated and to whom it shall be made
            available.

      B.    Perform complete weekly back-up of database files and programs and
            store in a location separate from the computer facility. Perform
            daily back-up of database files and programs and store on-site.

      C.    Provide the Project Officer read/print-only access to the repository
            database system via modem as requested.

      D.    Maintain (and update as necessary) the existing database management
            system (ORACLE RDBMS on a Hewlett-Packard 9000/800 G40 with the
            HP-UNIX operating system) on government furnished or approved
            central automated data processing system to integrate specimen
            information from all NIAID study sites and the specimen repository
            site.

      E.    Support and manage the NARDS system and database hardware and
            software. Utilize and/or modify the current data entry software
            modules for data entry of specimen specifications at the repository.
            Specifications include, but are not limited to: type of storage
            (i.e., mechanical freezer or liquid nitrogen); freezer, rack, and
            box numbers; sample position within the box; subject and site
            identification numbers; specimen collection date; type and volume of
            specimen; aliquot tracking; shipment or disbursement information;
            shipping problems; sample condition on receipt; and other data as
            requested by the Project Officer. Study sites shall provide both
            hard copy and electronic manifests for each shipment.

      F.    Maintain communications between the repository, study sites, data
            centers, central laboratories and Project Officer regarding
            reliability and timeliness of specimen identification, shipment,
            storage, and retrieval details.

Statement of Work (N01-AI-95381)                                  ATTACHMENT 1
08/16/99                                                           Page 3 of 3

<PAGE>

3.    Provide facilities and resources to store/handle/package specimens.

      A.    Provide sufficient floor space or vertical storage stacking system
            as needed in a single facility to accommodate up to 90 ADDITIONAL
            thirty-six cubic foot storage chest freezers (or their equivalent)
            and 45 ADDITIONAL liquid nitrogen freezers (added to those that will
            transfer from the incumbent contractor: see Offeror NOTE 10); a
            repair and spare-parts storage area measuring at least 200 square
            feet; a designated laboratory work area for handling HIV specimens
            under Biosafety Level 2 containment conditions (as per regulations
            in section 1.C); a receiving area and a packaging area measuring at
            least 200 square feet; and an office for system and data management
            activities.

      B.    Maintain and operate controlled freezers for -100 to -200 Celsius
            [C], -700 to -900 C, and -1200 to -1950 C (vapor phase, liquid
            nitrogen conditions). The Project Officer shall designate the
            specimen types stored in each temperature range. Three (3) spare,
            readily usable mechanical freezers and two (2) Liquid Nitrogen
            freezers which can be charged and ready for use shall be available
            for transfer of contents within 2 hours of the malfunction of an
            operating freezer.

      C.    Provide a central alarm system to monitor each freezer. This alarm
            system shall automatically contact a Refrigeration Engineer by
            telephone, and have an on-site audible alarm to alert personnel in
            the repository of a freezer malfunction. After notification, the
            engineer shall respond by being present to correct the alarm
            situation at the repository within one hour. Weekly tests shall be
            performed on the alarm system and the results included in the
            Quarterly Progress Report. Permanent printed records of storage
            temperatures and alarm condition reports noting events and actions
            taken shall be maintained at the facility.

      D.    Provide adequate electrical power to accommodate all mechanical
            freezers, the central alarm system, and the air conditioning system.
            There shall be a generator or generators on-site to handle the
            complete backup power supply in case of electrical power failure.
            All freezers, air conditioners and the central alarm system shall be
            electrically hooked-up so that should the power fail, complete power
            (capable of continuous operation for up to 48 hours) shall be
            immediately available from the generator(s).

       E.   Perform regular operational quality assurance maintenance for all
            cold storage equipment, the central alarm system, the air
            conditioning system, and the backup power system according to a
            Standard Operating Procedure approved by the Project Officer.
            Maintain a log of regular inspections and include inspection
            records/problems encountered/action taken results in the Quarterly
            Progress Report.

      F.    Provide security measures that ensure the facility and equipment
            against fire and personal intrusion.

4.    Provide training, instruction and oversight for all aspects of interaction
      between the repository and study sites.

      A.    Utilize and/or modify the current Standard Operating Procedures
            (SOPs) for all aspects of specimen handling as needed by study
            sites, including but not limited to, labeling, freezing, storing and
            shipping (at the request of the Project Officer).

      B.    Develop/update and maintain a User Manual that includes the SOPs and
            other guidance and reference materials relevant to specimen handling
            /shipping and their logging into the inventory database. The
            contents and format of the Manual shall be approved by the Project
            Officer prior to distribution. Development/update and distribution
            to study sites will be designated by the Project Officer to occur

Statement of Work (N01-AI-95381)                                  ATTACHMENT 1
08/16/99                                                           Page 4 of 3
<PAGE>

            within 120 days of the contract award date.

      C.    At the request of the Project Officer, provide operational
            information, participation at study group meetings (and other
            related group meetings), and training through telephone conference
            calls, on-site instruction, training sessions at study meetings,
            consultative interactions and periodic review.

5.    Report on progress, anticipated or existing problems, and discuss the work
      to be performed with the Project Officer.

6.    Follow Reporting Requirements. (Refer to ARTICLE C.2. REPORTING
      REQUIREMENTS)

7.    Contractor's key personnel shall meet with the Project Officer at periodic
      intervals after contract award to review Repository status.

8.    Ensure an orderly and safe transition of the Repository from the incumbent
      Contractor, at the beginning of the period of performance; and to a
      successor Contractor, at the end of the period of performance. Transition
      to a successor Contractor shall include all data files and source codes.

      A.    Provide, at the beginning of the contract term, for an orderly and
            safe transition from incumbent Contractor to the successful offeror,
            operate in accordance with approved SOPs and the contract Work
            Statement, and assist in the transfer of the following items from
            the incumbent:

            (1)   Government-owned equipment and property;

            (2)   Entire Repository inventory of stored specimens;

            (3)   National AIDS Repository Database System (NARDS);

            (4)   Supporting hardware and software documentation including
                  source codes;

            (5)   User manuals and training materials;

            (6)   Labeled and inventoried paper files.

      B.    No later than sixty (60) days after the beginning of this contract,
            The Contractor shall meet with the Project Officer to present
            recommendations for developing and/or implementing additional
            Standard Operating Procedures and/or a plan for revising current
            Standard Operating Procedures.

      C.    For an orderly and safe transition from this contract to the
            Government or its designee at the conclusion of this contract,
            deliver the following items by the expiration date of this contract:

            (1)   Government-owned equipment and property;

            (2)   National AIDS Repository Database System (NARDS);

            (3)   Supporting hardware and software documentation including
                  source codes;

            (4)   User manuals and training materials;

            (5)   Labeled and inventoried paper files, and

Statement of Work (N01-AI-95381)                                  ATTACHMENT 1
08/16/99                                                           Page 5 of 3

<PAGE>

            (6)   Entire Repository inventory of stored specimens.

           INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORTING
          INSTRUCTIONS FOR NIH COST-REIMBURSEMENT CONTRACTS, NIH(RC)-4

General: The contractor shall submit claims for reimbursement in the manner
and format described herein and as illustrated in the sample
invoice/financing request.

Format: Standard Form 1034, "Public Voucher for Purchases and Services Other
Than Personal," and Standard Form 1035, "Public Voucher for Purchases and
Services Other Than Personal -- Continuation Sheet," or reproduced copies of
such forms marked ORIGINAL should be used to submit claims for reimbursement.
In lieu of SF-1034 and SF-1035, claims may be submitted on the payee's
letter-head or self-designed form provided that it contains the information
shown on the sample invoice/financing request.

Number of Copies: As indicated in the Invoice Submission Clause in the
contract.

Frequency: Invoices/financing requests submitted in accordance with the
Payment Clause shall be submitted monthly unless otherwise authorized by the
contracting officer.

Cost Incurrence Period: Costs incurred must be within the contract
performance period or covered by precontract cost provisions.

Billing of Costs Incurred: If billed costs include: (l) costs of a prior
billing period, but not previously billed; or (2) costs incurred during the
contract period and claimed after the contract period has expired, the amount
and month(s) in which such costs were incurred shall be cited.

Contractor's Fiscal Year: Invoices/financing requests shall be prepared in
such a manner that costs claimed can be identified with the contractor's
fiscal year.

Currency: All NIH contracts are expressed in United States dollars. When
payments are made in a currency other than United States dollars, billings on
the contract shall be expressed, and payment by the United States Government
shall be made, in that other currency at amounts coincident with actual costs
incurred. Currency fluctuations may not be a basis of gain or loss to the
contractor. Notwithstanding the above, the total of all invoices paid under
this contract may not exceed the United States dollars authorized.

Costs Requiring Prior Approval: Costs requiring the contracting officer's
approval, which are not set forth in an Advance Understanding in the contract
shall be so identified and reference the Contracting Officer's Authorization
(COA) Number. In addition, any cost set forth in an Advance Understanding
shall be shown as a separate line item on the request.

Invoice/Financing Request Identification: Each invoice/financing request
shall be identified as either:

(a)    Interim Invoice/Contract Financing Request -- These are interim payment
       requests submitted during the contract performance period.

(b)    Completion Invoice -- The completion invoice is submitted promptly upon
       completion of the work; but no later than one year from the contract
       completion date, or within 120 days after settlement of the final
       indirect cost rates covering the year in which this contract is
       physically complete (whichever date is later). The completion invoice
       should be submitted when all costs have been assigned to the contract and
       all performance provisions have been completed.

(c)    Final Invoice -- A final invoice may be required after the amounts owed
       have been settled between the Government and the contractor (e.g.,
       resolution of all suspensions and audit exceptions).

Statement of Work (N01-AI-95381)                                  ATTACHMENT 1
08/16/99                                                           Page 6 of 3

<PAGE>

Preparation and Itemization of the Invoice/Financing Request: The contractor
shall furnish the information set forth in the explanatory notes below. These
notes are keyed to the entries on the sample invoice/financing request.

(a)    Designated Billing Office Name and Address -- Enter the designated
       billing office and address, identified in the Invoice Submission Clause
       of the contract, on all copies of the invoice/financing request.

(b)   Invoice/Financing Request Number -- Insert the appropriate serial number
      of the invoice/financing request.

(C)   Date Invoice/Financing Request Prepared -- Insert the date the
      invoice/financing request is prepared.

(d)   Contract Number and Date -- Insert the contract number and the effective
      date of the contract.

(e)   Payee's Name and Address -- Show the contractor's name (as it appears in
      the contract), correct address, and the title and phone number of the
      responsible official to whom payment is to be sent. When an approved
      assignment has been made by the contractor, or a different payee has been
      designated, then insert the name and address of the payee instead of the
      contractor.

(f)   Total Estimated Cost of Contract -- Insert the total estimated cost of the
      contract, exclusive of fixed-fee. For incrementally funded contracts,
      enter the amount currently obligated and available for payment.

(g)   Total Fixed-Fee -- Insert the total fixed-fee (where applicable). For
      incrementally funded contracts, enter the amount currently obligated and
      available for payment.

(h)   Billing Period -- Insert the beginning and ending dates (month, day, and
      year) of the period in which costs were incurred and for which
      reimbursement is claimed.

(I)   Incurred Cost - Current -- Insert the amount billed for the major cost
      elements, adjustments, and adjusted amounts for the current period.

(j)   Incurred Cost - Cumulative -- Insert the cumulative amounts billed for the
      major cost elements and adjusted amounts claimed during this contract.

(k)   Direct Costs -- Insert the major cost elements. For each element, consider
      the application of the paragraph entitled "Costs Requiring Prior Approval"
      on page 1 of these instructions.

      (l)   Direct Labor -- Include salaries and wages paid (or accrued) for
            direct performance of the contract. For Key Personnel, list each
            employee on a separate line. List other employees as one amount
            unless otherwise required by the contract.

      (2)   Fringe Benefits -- List any fringe benefits applicable to direct
            labor and billed as a direct cost. Fringe benefits included in
            indirect costs should not be identified here.

      (3)   Accountable Personal Property -- Include permanent research
            equipment and general purpose equipment having a unit acquisition
            cost of $1,000 or more and having an expected service life of more
            than two years, and sensitive property regardless of cost (see the
            DHHS CONTRACTOR'S GUIDE FOR CONTROL OF GOVERNMENT PROPERTY). Show
            permanent research equipment separate from general purpose
            equipment. Prepare and attach Form HHS-565, "Report of Accountable
            Property," in accordance with the following instructions:

         List each item for which reimbursement is requested. A reference shall
be made to the following (as applicable):

      -     The item number for the specific piece of equipment listed in the
            Property Schedule.

      -     The Contracting Officer's Authorization letter and number, if the
            equipment is not covered by the Property Schedule.

NIH(RC)-4                                                          ATTACHMENT 2
Rev. 5/97
<PAGE>

      -     Be preceded by an asterisk (*) if the equipment is below the
            approval level.

      (4)   Materials and Supplies -- Include equipment with unit costs of less
            than $1,000 or an expected service life of two years or less, and
            consumable material and supplies regardless of amount.

      (5)   Premium Pay -- List remuneration in excess of the basic hourly rate.

      (6)   Consultant Fee -- List fees paid to consultants. Identify consultant
            by name or category as set forth in the contract's Advance
            Understanding or in the COA letter, as well as the effort (i.e.,
            number of hours, days, etc.) and rate being billed.

      (7)   Travel -- Include domestic and foreign travel. Foreign travel is
            travel outside of Canada, the United States and its territories and
            possessions. However, for an organization located outside Canada,
            the United States and its territories and possessions, foreign
            travel means travel outside that country. Foreign travel must be
            billed separately from domestic travel.

      (8)   Subcontract Costs -- List subcontractor(s) by name and amount
            billed.

      (9)   Other -- List all other direct costs in total unless exceeding
            $1,000 in amount. If over $1,000, list cost elements and dollar
            amounts separately. If the contract contains restrictions on any
            cost element, that cost element must be listed separately.

(l)   Cost of Money (COM) -- Cite the COM factor and base in effect during the
      time the cost was incurred and for which reimbursement is claimed.

(m)   Indirect Costs--Overhead -- Identify the cost base, indirect cost rate,
      and amount billed for each indirect cost category.

(n)   Fixed-Fee Earned -- Cite the formula or method of computation for the
      fixed-fee (if any). The fixed-fee must be claimed as provided for by the
      contract.

(o)   Total Amounts Claimed -- Insert the total amounts claimed for the current
      and cumulative periods.

(p)   Adjustments -- Include amounts conceded by the contractor, outstanding
      suspensions, and/or disapprovals subject to appeal.

(q)   Grand Totals

The contracting officer may require the contractor to submit detailed support
for costs claimed on one or more interim invoices/financing requests.

FINANCIAL REPORTING INSTRUCTIONS:

These instructions are keyed to the Columns on the sample invoice/financing
request.

Column A--Expenditure Category - Enter the expenditure categories required by
the contract.

Column B--Cumulative Percentage of Effort/Hrs.-Negotiated - Enter the
percentage of effort or number of hours agreed to doing contract negotiations
for each employee or labor category listed in Column A.

Column C--Cumulative Percentage of Effort/Hrs.-Actual - Enter the percentage
of effort or number of hours worked by each employee or labor category listed
in Column A.

Column D--Incurred Cost-Current - Enter the costs, which were incurred during
the current period.

NIH(RC)-4                                                          ATTACHMENT 2
Rev. 5/97
<PAGE>

Column E--Incurred Cost-Cumulative - Enter the cumulative cost to date.

Column F--Cost at Completion - Enter data only when the contractor estimates
that a particular expenditure category will vary from the amount negotiated.
Realistic estimates are essential.

Column G--Contract Amount - Enter the costs agreed to during contract
negotiations for all expenditure categories listed in Column A.

Column H--Variance (Over or Under) - Show the difference between the
estimated costs at completion (Column F) and negotiated costs (Column G) when
entries have been made in Column F. This column need not be filled in when
Column F is blank. When a line item varies by plus or minus 10 percent, i.e.,
the percentage arrived at by dividing Column F by Column G, an explanation of
the variance should be submitted. In the case of an overrun (net negative
variance), this submission shall not be deemed as notice under the Limitation
of Cost (Funds) Clause of the contract.

Modifications: Any modification in the amount negotiated for an item since
the preceding report should be listed in the appropriate cost category.

Expenditures Not Negotiated: An expenditure for an item for which no amount
was negotiated (e.g., at the discretion of the contractor in performance of
its contract) should be listed in the appropriate cost category and all
columns filled in, except for G. Column H will of course show a 100 percent
variance and will be explained along with those identified under H above.

NIH(RC)-4                                                          ATTACHMENT 2
Rev. 5/97
<PAGE>

        SAMPLE INVOICE/FINANCING REQUEST AND CONTRACT FINANCIAL REPORT

<TABLE>
<S>                                                    <C>
(a)    Billing Office Name and Address                 (b) Invoice/Financing Request No.__________________________

       NATIONAL INSTITUTES OF HEALTH
       National Institute of Allergy and Infectious    (C) Date Invoice Prepared__________________________________
       Diseases, CMB
       6700-B Rockledge Drive, Room 2230, MSC 7612
       Bethesda, MD 20892-7612                         (d) Contract No.___________________________________________

(e)    Payee's Name and Address                            Effective Date_________________________________________
       ABC CORPORATION
       100 Main Street                                 (f) Total Estimated Cost___________________________________
       Anywhere, USA zip code
                                                       (g) Total Fixed Fee________________________________________
Attn:  Name, Title, & Phone Number of Official to
       Whom Payment is Sent

(h) This invoice/financing request represents reimbursable costs for the period from _________ to _________
</TABLE>
<TABLE>
<CAPTION>
   Expenditure Category*          Cumulative Percentage          Incurred Cost                  Cost at      Contract     Variance
             A                       of Effort/Hrs.                                            Completion     Amount          H
                                                                                                   F            G
                                 ----------------------   -------------------------------
                                 Negotiated     Actual    (I) Current      (j) Cumulative
                                      B            C            D                E
------------------------------   ----------     ------    -----------      ---------------     ----------    --------     ---------
<S>                              <C>            <C>       <C>              <C>                 <C>           <C>          <C>
(k) Direct Costs:
    (1) Direct Labor
    (2) Fringe Benefits
    (3) Accountable Property
        (attach HHS-565)
    (4) Materials & Supplies
    (5) Premium Pay
    (6) Consultant Fees
    (7) Travel
    (8) Subcontracts
    (9) Other
Total Direct Costs
(l) Cost of Money
(m) Overhead
    G&A
(n) Fixed Fee
(o) Total Amount Claimed
(p) Adjustments
(q) Grand Totals

</TABLE>

I certify that all payments are for appropriate purposes and in accordance with
the contract.

       ---------------------------   --------------------
       (Name of Official)           (Title)

* Attach details as specified in the contract

NIH(RC)-4                                                          ATTACHMENT 2
Rev. 5/97

<PAGE>

           PHS 352.223-70 SAFETY AND HEALTH (DEVIATION) (AUGUST 1997)

(a)   To help ensure the protection of the life and health of all persons, and
      to help prevent damage to property, the Contractor shall comply with all
      Federal, State and local laws and regulations applicable to the work being
      performed under this contract. These laws are implemented and/or enforced
      by the Environmental Protection Agency, Occupational Safety and Health
      Administration and other agencies at the Federal, State and local levels
      (Federal, State and local regulatory/enforcement agencies).

(b)   Further, the Contractor shall take or cause to be taken additional safety
      measures as the Contracting Officer in conjunction with the project or
      other appropriate officer, determines to be reasonably necessary. If
      compliance with these additional safety measures results in an increase or
      decrease in the cost or time required for performance of any part of work
      under this contract, an equitable adjustment will be made in accordance
      with the applicable "Changes" Clause set forth in this contract.

(c)   The Contractor shall maintain an accurate record of, and promptly report
      to the Contracting Officer, all accidents or incidents resulting in the
      exposure of persons to toxic substances, hazardous materials or hazardous
      operations; the injury or death of any person; and/or damage to property
      incidental to work performed under the contract AND all violations for
      which the Contractor has been cited by any Federal, State or local
      regulatory/enforcement agency. The report shall include a copy of the
      notice of violation and the findings of any inquiry or inspection, and an
      analysis addressing the impact these violations may have on the work
      remaining to be performed. The report shall also state the required
      action(s), if any, to be taken to correct any violation(s) noted by the
      Federal, State or local regulatory/enforcement agency and the time frame
      allowed by the agency to accomplish the necessary corrective action.

(d)   If the Contractor fails or refuses to comply promptly with the Federal,
      State or local regulatory/enforcement agency's directive(s) regarding any
      violation(s) and prescribed corrective action(s), the Contracting Officer
      may issue an order stopping all or part of the work until satisfactory
      corrective action (as approved by the Federal, State or local
      regulatory/enforcement agencies) has been taken and documented to the
      Contracting Officer. No part of the time lost due to any stop work order
      shall be subject to a claim for extension of time or costs or damages by
      the Contractor.

(e)   The Contractor shall insert the substance of this clause in each
      subcontract involving toxic substances, hazardous materials, or
      operations. Compliance with the provisions of this clause by
      subcontractors will be the responsibility of the Contractor.

                                 (End of clause)

Safety and Health Clause (Deviation)                            ATTACHMENT 3
PHS 352.223-70, (8/97)

<PAGE>

                        PROCUREMENT OF CERTAIN EQUIPMENT

Notwithstanding any other clause in this contract, the Contractor will not be
reimbursed for the purchase, lease, or rental of any item of equipment listed
in the following Federal Supply Groups, regardless of the dollar value,
without the prior written approval of the Contracting Officer.

            67 -  Photographic Equipment
            69 -  Training Aids and Devices
            70 -  General Purpose ADP Equipment, Software, Supplies and
                  Support (Excluding 7045-ADP Supplies and Support Equipment.)
            71 -  Furniture
            72 -  Household and Commercial Furnishings and Appliances
            74 -  Office Machines and Visible Record Equipment
            77 -  Musical Instruments, Phonographs, and Home-type Radios
            78 -  Recreational and Athletic Equipment

When equipment in these Federal Supply Groups is requested by the Contractor
and determined essential by the Contracting Officer, the Government will
endeavor to fulfill the requirement with equipment available from its excess
personal property sources, provided the request is made under a
cost-reimbursement contract. Extensions or renewals of approved existing
leases or rentals for equipment in these Federal Supply Groups are excluded
from the provisions of this article.

NIH(RC)-7  (4/1/84)                                         ATTACHMENT 4
OMB Bulletin 81-16

<PAGE>

                  SCHEDULE II-A - GOVERNMENT FURNISHED PROPERTY

<TABLE>
<CAPTION>

ITEM             DESCRIPTION                          MANUFACTURER             MODEL NUMBER         QUANTITY
<S>      <C>                                          <C>                      <C>                  <C>
----------------------------------------------------------------------------------------------------------------------
GENERAL REPOSITORY EQUIPMENT
1        BIOLOGICAL SAFETY CABINET                       CCI                   740                  2
2        WATER BATHS                                     ELEMCO                70                   2
3        -70(DEGREE)MECHANICAL FREEZER WITH RACKS        REVCO                 ULT2090EN            28
4        -70(DEGREE)MECHANICAL FREEZER WITH RACKS        HARRIS                HLT19LS85            17
5        LN2 FREEZER WITH RACKS                          MVE                   A4500                12
6        LN2 FREEZER WITH RACKS                          MVE                   XLC-1840             5
7        LN2 CRYOGENIC SHIPPER                           MVE                   TA-60                2
8        -70(DEGREE)MECHANICAL FREEZER WITH RACKS        RUSH                  3185                 8
9        LN2 CRYOGENIC SHIPPER                           CUSTOM BIOGENICS      DS-3                 3
10       LN2 CRYOGENIC SHIPPER                           TAYLOR-WHARTON        CP65                 4
11       LN2 FREEZER WITH RACKS                          TAYLOR-WHARTON       33K                   7
12       LN2 BULK STORAGE TANK                           MVE                  VVXC3000NC1           1
13       VACUUM JACKETED LN2 DISTRIBUTION PIPE           MVE                  NONE                  1
14       -70(DEGREE)MECHANICAL FREEZER WITH RACKS        HARRIS               HLT-36LS86            15
15       PLASTIC SHIPPING CASE FOR LN2 SHIPPER           MVE                  NONE                  1
16       LN2 FREEZER WITH RACKS                          TAYLOR-WHARTON       38KM21                7
17       DOT CERTIFIED DRY ICE SHIPPING CONTAINER        U.S. ARMY            FSSU-21               15 (APPROX.)
18       DOT CERTIFIED DRY ICE SHIPPING CONTAINER        U.S. ARMY            FSSU-4                5 (APPROX.)
COMPUTER HARDWARE, SOFTWARE AND DATA COMMUNICATIONS EQUIPMENT
1        9000/800 G40 BUSINESS SERVER WITH               HEWLETT-             9000/G40              1
         128 MB RAM, 7 GB HARD DISK STORAGE,             PACKARD
         DAT CARTRIDGE TAPE DRIVE, CD-ROM DRIVE, 16
         PORT MUX, HP-IB INTERFACE

</TABLE>

Government Furnished Property                                  ATTACHMENT 5
Schedule II-A (8/16/99)                                         Page 2 of 3
<PAGE>
<TABLE>
<S>      <C>                                          <C>                      <C>                  <C>
----------------------------------------------------------------------------------------------------------------------
2        HP-UNIX OPERATING SYSTEM SOFTWARE               HEWLETT-PACKARD      V10.20                1
3        ORACLE RDBMS SOFTWARE                           ORACLE               V7.3                  1
4        CASE DESIGNER 2000 SOFTWARE                     ORACLE               NONE                  1
5        CASE DEVELOPER 2000 SOFTWARE                    ORACLE               NONE                  1
6        ANSI C COMPILER                                 HEWLETT-PACKARD      NONE                  1
7        POWERMON SOFTWARE                               SYSTEMS             V1.3                   1
                                                         ENHANCEMENT
                                                         CORPORATION
8        X-TERMINAL                                      HEWLETT-PACKARD     A1097C                 1
9        ENVIZEX COMPUTER TERMINAL                       HEWLETT-PACKARD     D1196A                 4
10       ENTRIA WORKSTATION                              HEWLETT-PACKARD     C3264A                 1
11       COMPUTER TERMINAL                               DEC                 VT420-CA               2
12       UNINTERRUPTIBLE POWER SUPPLY FOR HP             DEC                 NONE                   1
13       GATEWAY 2000 PERSONAL COMPUTER WITH PENTIUM     GATEWAY             4DX-33                 1
         OVERDRIVE CHIP, 32 MB RAM, 200 MB AND 1.6 GB
         HDS, DUAL FLOPPY DRIVE, CD-ROM DRIVE, LAN
         CARD, INTERNAL FAX-MODEM, AND COLOR MONITOR
14       COMPAQ PRESARIO PERSONAL COMPUTER WITH PENTIUM  COMPAQ              PRESARIO               1
         CHIP, 32 MB RAM, 4.3 GB HD, FLOPPY DRIVES,
         CD-ROM, LAN CARD, INTERNAL FAX-MODEM, AND
         COLOR MONITOR
15       WINDOWS 95 SOFTWARE                             MICROSOFT           WINDOWS 95             2
</TABLE>

<PAGE>
<TABLE>
<S>      <C>                                          <C>                      <C>                  <C>
----------------------------------------------------------------------------------------------------------------------
16       WORDPERFECT SUITE 7                             COREL               V7.0                   2
17       DBMS/COPY                                       SPSS, INC.          V5.0                   1
18       SMARTERM ESSENTIALS                             PERSOFT, INC.       V7.0                   2
19       PLATINUM DB MONITORING SW FOR HP G40            PLAT.TECHNOLOGIES   V3.1                   1
20       14400 BAUD EXTERNAL MODEM                       PRACTICAL           PM14400FXMT
                                                         PERIPHERALS
21       POWER SURGE PROTECTOR                           TRIPPE              ISOBAR 4               1
22       DOT MATRIX PRINTER                              DEC                 LA-424                 1
23       PRINTER WITH POSTSCRIPT AND 4 MB RAM MODULES    HEWLETT-PACKARD     LASERJET 4             1
24       EXTERNAL CASSETTE TAPE DRIVE FOR COMPAQ         IOMEGA DITTO        EASY 3200              1
25       SMART 650VA UNINTERRUPTIBLE POWER SUPPLY FOR PC APC                 VS650                  2
26       BAR CODE SCANNER                                AMERICAN            5310HP4342             1
                                                         MICROSYSTEMS
27       DELTA PLUS LABEL PRINTER                        ELTRON              TLP2642PSA             1
28       LABEL WORKS SOFTWARE                            AMERICAN            V2.0                   1
                                                         MICROSYSTEMS
29       DESKPRO PERSONAL COMPUTER WITH 1 MB RAM,        COMPAQ              286E                   1
         FLOPPY DRIVES, 40 MB HARD DRIVE, AND
         MONOCHROME MONITOR
30       PAPER COPIER                                    MINOLTA             EP-2121                1
31       PLAIN PAPER FACSIMILE MACHINE                   MURATEC             F-86                   1
32       LASER JET COLOR PRINTER                         HEWLETT-PACKARD     5M                     1

</TABLE>

Government Furnished Property                                  ATTACHMENT 5
Schedule II-A (8/16/99)                                         Page 4 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]